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Talent will not; nothing is more common than unsuccessful men with talent.  
Genius will not; unrewarded genius is almost a proverb.  
Education will not; the world is full of educated derelicts.  
Persistence and determination alone are omnipotent”. 
Calvin Coolridge, President of the United States 1923-1929 
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Abstract 
Despite major advances, chronic lymphocytic leukemia (CLL) is still considered incurable. 
Fludarabine refractory patients and those with TP53 disruptions have a particularly poor prognosis. 
Alemtuzumab is an established treatment option for these patients. However, its use is complicated 
by immunosuppressive side effects. New drugs targeting cellular pathways are currently developed 
but there are few manufacturer-independent comparative experiments. 
The aim of this thesis is to gain an insight into the outcome of patients with advanced CLL and 
to explore new emerging drugs. 
In the first study, the natural history of advanced CLL in a well-defined region without external 
referrals was retrospectively investigated. All patients diagnosed with CLL 1991-2010 were 
screened and those with bulky fludarabine refractory (BFR) and double (i.e. fludarabine and 
alemtuzumab) refractory (DR) CLL were identified. Subjects were primary referrals within the 
Stockholm region. The ORR to salvage therapy was 20% and the median time to treatment failure 
was 6 months, both significantly lower in BFR/DR patients than in non-BFR/DR patients. Median 
overall-survival (OS) was 18 months; 29 months in BFR vs 13 months in DR. Our results on 
consecutive patients in routine clinical practice may facilitate interpretation of non-randomized trials 
on novel drugs in advanced-stage CLL. 
In the second study, the safety and efficacy of alemtuzumab, when used in routine health care 
in relapsed/refractory patients at experienced medical centres in a defined region, was evaluated. 
Records from patients diagnosed within the Stockholm region year 2000-2010 were retrospectively 
screened. Files from alemtuzumab treated patients were analysed in detail. Patients were heavily 
pretreated and the majority had fludarabine refractory disease. The median cumulative dose of 
alemtuzumab was 930 mg and median duration of therapy was 12 weeks. The ORR was 43% and a 
higher dose was associated with higher response rate. Median OS was 22.5 months. Compared with 
the results from previous reports, we observed a higher cumulative dose/longer duration of therapy, 
numerically higher response rates as well as longer survival in our regional, consecutive patients. 
Our results suggest that optimal patient management and patient identification may result in 
avoidance of early discontinuation of planned therapy and possibly better treatment outcomes. 
In the third study, the safety and efficacy of lenalidomide in combination with alemtuzumab 
was explored in a phase I study and additionally, the capacity of low-dose lenalidomide in 
maintaining immune functions in advanced-stage CLL patients prior and during alemtuzumab was 
evaluated. Tumor flare reaction occurred in some patients but there was no evidence of tumor lysis 
syndrome. The combination showed an acceptable safety profile as well as clinical activity with an 
overall response rate of 42%. Median progression free survival was 5 months, exceeding 12 months 
in 3 patients. T-cell stimulation as well as a decreased number of regulatory T cells was evident on 
low dose lenalidomide. Our results provide the basis for an extended phase 2 trial on this 
combination of drugs as well as further studies on lenalidomide as an immune-enhancing agent.  
In the fourth study, we provide a manufacturer independent, head-to-head comparison on 
sensitivity of CLL cells to a panel of emerging small targeted therapeutic molecules using high-
throughput screening based on an automated fluorescence digital scanning system. Fresh CLL cells 
from patients with indolent or progressive disease were cultured in a unique primary cell-culture 
medium and the in vitro anti-tumor effects of 31 small therapeutic molecules were compared. The 
sensitivity to each drug showed considerable inter-patient variability. Highest mean direct killing 
was observed with one survivin inhibitor (YM-155), 2 BCL-2 inhibitors (ABT-199, ABT 737) and 
one selective CDK inhibitor (dinaciclib). Their killing capacity was similarly high in refractory and 
untreated patients and was significantly higher in cells with TP53 disruptions. Sensitivity in bone 
marrow showed a high correlation to that in blood. Our results may help to identify drugs of 
particular interest for further clinical development. 
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1 CHRONIC LYMPHOCYTIC LEUKEMIA 
1.1 Introduction 
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western World 
and is mainly a disease of the elderly. It is characterized by a neoplastic clonal expansion of 
CD5+ and CD23+, morphological mature B-lymphocytes which accumulate in the blood, 
bone marrow and lymphoid tissues [1]. CLL is biologically and clinically a very 
heterogeneous disease where some patients never require therapy and some patients display 
an aggressive course with poor response to therapy and death within months. Despite recent 
major advances in understanding the pathogenesis and in the management of CLL, relapse 
ultimately occurs in almost all patients who require therapy and the disease remains 
incurable [2]. 
1.2 Epidemiology 
CLL has a high incidence in Europe and North America, being the most common leukemia 
in the Western World but is rarer among people of Asian or African origin and with nearly 
twice the incidence in men as in women [1, 3]. In Sweden, it affects about 500 inhabitants per 
year [4]. CLL is mainly a disease of the elderly and the prevalence increases dramatically 
with age. In Sweden the median age of diagnosis is 71. 
1.3 Etiology 
The etiology of CLL remains unknown. The most obvious risk factor is age but there is 
strong evidence that a genetic component contributes as a family history of CLL or other 
lymphoid malignancies is stated a risk factor [5]. Regarding environmental factors, the 
relationship remains rather weak even though some associations to pesticides, magnetic 
fields, farming and animal breeding [6-8] and viruses [9, 10] have been found. There is 
evidence that CLL may be driven by both antigen [11] and cell-autonomous signaling [12, 13] 
which both will be discussed further in the following chapters. 
1.4 Pathogenesis 
1.4.1 Monoclonal B cell lymphocytosis (MBL) 
MBL is considered an essential pre-leukemic state of CLL representing the asymptomatic 
proliferation of clonal B cells with circulating numbers < 5x109/L and absence of 
lymphadenopathy or disease-related symptoms [14]. MBL is cytometrically indistinguishable 
from CLL and the prevalence is known to increase with age and ranges from < 1% to about 
16% depending on the evaluated population and detection methods [14]. MBL may progress 
to CLL at a rate of 1-2% per year [15] and the vast majority of CLL patients exhibit such a 
precursor state for 6 months to 7 years [16]. Most MBL clones also exhibit a genotype 
similar to that of CLL [14]. Recent data suggest that certain driver mutations within 
subclones foster development to CLL [17]. 
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1.4.2 Clonal evolution 
Malignancies develop through multistep acquisition of critical mutations. Therefore the 
precursor cell in most cases needs a long life span to accumulate the required number of 
mutations. Next generation sequencing (NGS) techniques have demonstrated that somatic 
mutations could be accumulated within hematopoietic stem cells (HSC) and the number 
increases with age [18]. In addition, premalignant clones carrying somatic mutations have 
been detected in phenotypically normal HSC populations in acute myelogenous leukemia 
[19]. Thus, HSCs are considered to be the origin of several myeloid malignancies. 
In contrast, CLL has been considered to originate from differentiated mature 
lymphocytes. However, HSCs from CLL patients have been shown to give rise to mono- or 
oligoclonal mature B cells, which simulate MBL, in mice. The generated B cell clones 
were independent of the original CLL clones with respect to VDJ genes. In addition, 
GEP analysis showed a skewed lymphoid gene expression compared with normal adult 
HSCs [20]. The first oncogenic event from MBL to CLL remains unknown but these 
findings and existence of oligoclonal B cell clones in both MBL and CLL suggests that the 
propensity to generate clonal B cells might have been acquired as far back as self-renewing 
HSC with germline IGH genes [20]. However, further studies are warranted to clarify the 
precise molecular mechanisms enabling HSCs to propagate malignant clones. 
The complexity of CLL clonal architecture and the proof-of principle that genetically 
diverse subclones, not detectable by conventional methods, may be admixed with the 
dominant leukemic clone have been disclosed by recent genomic studies [21]. NGS has 
made detection of a small fraction of mutated clones (< 20%) possible. In a recent study 
subclonal TP53 mutations were detected in 9% of untreated patients and these patients 
experienced the same clinical phenotype and poor survival as those with clonal TP53 
lesions. By time small TP53 mutated subclones detected before treatment initiation became 
the predominant population and anticipated the development of chemorefractory CLL 
among patients requiring treatment [22]. This finding confirms the pathogenic effect of 
subclones and that clinically important mutations may be present at diagnosis but only 
become evident over time through selective pressure. In conclusion, CLL is not a static 
disease it has a clonal architecture that changes over time, influenced by selection 
pressures. Subclonal mutations in CLL may contribute to the variations observed in disease 
tempo and response to therapy [21, 22]. 
1.4.3 B cell receptor 
Normal as well as malignant B cells, display B cell receptors (BCRs) on their surfaces. The 
BCR is composed of the antigen-specific surface membrane immunoglobulin M (sIgM) 
and the heterodimers CD79a and CD79b. In the normal B cell development process, 
activated B cells undergo massive clonal expansion, accompanied by the activation of 
somatic hypermutation (SHM) in the immunoglobulin (Ig) variable region genes, in the 
germinal centers (GC) [23]. B cells that have acquired BCR affinity-increasing mutations are 
selected by interaction with micorenvironmental cells through the α4β1/VCAM-1 (vascular 
cell adhesion molecule-1) axis, others undergo apoptosis. Thereafter many selected B cells 
undergo class switch recombination of their Ig heavy chain constant region genes. Normal 
naïve B cells express functional sIgM and sIgD and after class-switch expression of other 
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classes of immunoglobulins may occur [23]. The process (proliferation, SHM and class 
switch) undergo multiple rounds until B cells differentiate in either memory B cells or 
plasma cells and leave the GC [1]. 
CLL cells have somatically mutated Ig variable region genes indicating that the cell of 
origin has passed through the germinal center [1] even though it is not completely clear 
whether SHM of B cells takes place only in the GC [24]. Characterized by the number of 
somatic hypermutations in the heavy chain variable region of immunoglobulin genes 
(IGHV), high or low, two major molecular subtypes of CLL can be distinguished. A ≥ 98% 
similarity of the IGHV gene with the corresponding germline sequence is termed 
“unmutated CLL” and < 98% homology is called “mutated CLL” [25, 26]. Approximately 
50% of the patients belong to each group and clinical differences have been associated with 
IGHV mutational status [25-27]. Recent gene expression profile (GEP) analysis pointed to 
CD5+ B cells as the precursor population of CLL [28]. Stereotyped BCR, a characteristic of 
CLL, is also enriched in CD5+ B cells compared with conventional B cells. However, most 
CD5+ B cells are regarded as pre-GC lymphocytes with unmutated IGHV genes [29] 
however a small fraction co-expresses CD27, a verified marker of somatic mutations (i.e. a 
memory B cell marker) [28, 30]. CD5+CD27+ and CD5+CD27- B cells display a similar GEP 
which may indicate that CD5+CD27+ B cells derive from CD5+CD27- B cells that  can 
undergo GC reactions [28]. 
Both normal CD27+ cells and mutated IGHV CLL carry BCL6 mutations, a genetic 
trait of a GC passage, in the same frequency as memory B cells [28, 31] supporting the 
hypothesis that IGHV mutated CLL derives from post-GC CD5+ memory B cells. Detailed 
GEP as well as the pattern of gene mutations indicate that mutated IGHV CLL may derive 
from CD5+CD27+ B cells and unmutated IGHV CLL derives from CD5+CD27- B cells [28, 
32]. The distribution of stereotyped IGHV rearrangements, with lower frequency in the 
mutated CLL/mutated CD5+CD27+ B cell group compared to the unmutated CLL/ 
unmutated CD5+CD27- B cell group respectively, also supports this hypothesis [28]. 
Between the two subgroups of mutated and unmutated CLL, there are several 
biological differences (described in sections below) resulting in higher degree of signaling 
downstream the Ig receptor in unmutated CLL. 
1.4.4 Antigens 
The similarities between the normal memory B cell and the CLL cells, mutated as well as 
unmutated, indicate that CLL cells originate from antigen-experienced B cells [32]. This 
suggests that an antigen-driven process contributes to CLL pathogenesis. The hypothesis is 
supported by the finding that approximately 30% of the patients have strikingly similar 
BCRs and in 1% of the cases the Igs are nearly identical [33-36]. These, so called stereotyped, 
receptors are defined by highly homologous heavy and light chain complementarity-
determining region 3 (CDR3) (the main determinant for antigen specificity) amino acid 
sequences as well as confined V-gene usage. Either presence or absence of somatic 
mutations strongly suggests that a set of common antigens contributes to CLL pathogenesis  
[33-35]. Stereotyped receptors are more frequent in unmutated than in mutated CLL cases and 
the presence of stereotyped BCRs also seems to affect prognosis, most convincingly 
demonstrated for the IGHV subgroup IGHV3-21 [33, 34, 37] (see 1.10.2). Mutated IGHV CLL 
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cases display oligo- or mono-reactive BCRs binding with high-affinity to restricted, more 
specific antigens whereas unmutated cases show poly-reactive BCRs with low-affinity 
binding to a broader range of self-antigens [38]. Several antigens have been suggested to 
drive the malignant process, exogenous as well as autoantigens. Examples of antigens are 
modified cytoskeletal proteins and oxidation-specific epitopes, i.e. molecular motifs on 
apoptotic cells, and polysaccharides from Streptococcus pneumoniae for example [39]. A 
link between Epstein-Barr virus (EBV) and cytomegalovirus (CMV) and utilization of 
IGHV4-34 gene has also been discussed [40]. 
1.4.5 Autonomous signaling 
Despite indications that CLL is driven by an antigen mediated process, there are increasing 
evidence implicating BCR induced antigen-independent signaling in CLL. The BCRs may 
induce autonomous signaling dependent on the VH CDR3 structure and a specific epitope 
located there [13, 41]. Approximately 50% of CLL patients express such self-recognizing 
epitopes which cause a tonic, constitutive and autonomous signal of the BCR [13]. Recent 
data confirmed that CLL cells have a higher basal signaling than normal B cells and that 
basal signaling was particularly increased in IGHV mutated CLL cells [12]. Even though the 
relevance of autonomous interactions in vivo, where CLL cells are surrounded by high 
levels of serum Ig, is unclear it might contribute to CLL pathogenesis in concert with 
extrinsic ligands. In contrast to other B-cell malignancies, CLL cells do not have any 
activating mutations in BCR genes, suggesting that both autonomous signaling and external 
antigens contribute to the receptor stimulation [42]. 
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1.5 Signal transduction in CLL 
 
Figure 1. Molecular pathways involved in the pathogenesis of CLL. The BCR is composed of a 
membrane immunoglobulin bound to CD79A and CD79B. Antigen binding induces signaling initiation by the 
recruitment of SYK and LYN to the ITAM domains of CD79A/CD79B, and the subsequent activation of 
BTK and PLCγ leading to downstream activation of MAPK, PI3K/AKT or NF-κB signaling. Upon ligand 
binding of the TLRs receptor specific adapters, such as MYD88 are recruited leading to activation of NF-κB 
signaling. Upon ligand binding, NOTCH signaling is initiated by a series of proteolytic cleavages that lead to 
the formation of a complex that drives the transcription of target genes. NF-κB activation is achieved through 
either the canonical or non-canonical pathways. In the non-canonical pathway, for example BIRC3 is 
recruited to the active receptors, allowing the release and stabilization of MAP3K14 that, in turn, leads to the 
activation of NF-κB signaling.  
Genes harboring somatic lesions in CLL are highlighted in blue. 
Reprinted from Immunology Letters, Volume 155, Issues 1–2, Sept–Oct 2013, Pages 51-55, Rossi D et al,  
Molecular bases of chronic lymphocytic leukemia in light of new treatments, with permission from Elsevier. 
 
1.5.1 B Cell Receptor and downstream signaling 
The BCR is a key factor in CLL [43-45] pathogenesis. As previously described, B cells 
expressing BCRs with high affinity are also those with an integrin-mediated signal 
sufficient to rescue them from apoptosis [46]. Antigen binding to the sIgM induces the 
formation of signalosomes associated with activation of immunoreceptor tyrosine based 
activation motifs (ITAM) in the tails of CD79a and CD79b by LYN (Lck/Yes Novel 
tyrosine kinase) and spleen tyrosine kinase (SYK) activation. B-cell linker protein (BLNK) 
propagates the signal further to the downstream signaling components Bruton’s tyrosine 
kinase (BTK) and phospholipase C gamma 2 (PLCγ2) leading to calcium mobilization and 
the activation of several downstream pathways including mitogen-activated protein kinases 
(MAPK), anti-apoptotic protein kinase (AKT) and nuclear factor kappa-light-chain-
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enhancer of activated B cells (NFκB) (Figure 1). These events in turn lead to activation of 
transcriptional factors and changes in gene expression promoting survival, proliferation and 
differentiation [42, 47]. LYN also phosphorylates the cytoplasmic domain of CD19 which 
downstream activates PI3K (phosphatidylinositol-3-kinase) and the subsequent pathway as 
well as promotes BCR aggregation. LYN has also a negative feed-back regulatory function 
on BCR signaling [42, 43]. BTK is a non-receptor tyrosine kinase, particularly expressed in B 
cells and BTK deficiency leads to low serum Ig levels and lack of peripheral B cells. BTK 
requires two signals for activation, a recruitment signal by PI3K and an activation signal by 
LYN/SYK. The activation of BTK is critical for the amplification of the BCR signaling and 
results in activation of transcription factors necessary for B cell proliferation and 
differentiation [42, 43, 45, 48, 49]. The expression of BTK is upregulated upon BCR activation as 
well as stimulation of toll like receptors or CD40 by CD40L on T cells [49]. In addition, 
BTK regulates BCR controlled integrin-mediated interactions such as those with VCAM-1 
and fibronectin in the microenvironment as well as chemokine controlled signaling via 
chemokine receptor 4 (CXCR4) in vitro and in vivo thereby possibly also affecting 
adhesion and migration [48-50]. Gene expression of BTK is elevated in CLL compared to 
normal B cells. 
In normal cells BCR signaling duration and intensity is tightly regulated by numerous 
mechanisms including receptor endocytosis and negative regulatory co-receptors (for 
example CD5) which modulate the functional outcome of the response [42]. The BCR 
downstream consequences depend on signal strength and the effectors of BCR activation 
are differently activated depending on the antigen ligated. Outcome ranges from a low level 
antigen-independent “tonic” signal essential for survival to a strong antigen-mediated 
signal which drives the cell toward proliferation via effects on key regulators such as 
myelocytomatosis oncogene (MYC), myeloid cell leukemia sequence 1(MCL1) and BCL-2 
like 11 (BIM), survival or apoptosis [51-53]. Increased basal BCR signaling is a strategy of 
the immune system for silencing autoreactive B cells [54]. The level of basal cell 
autonomous signaling is higher in CLL cells compared to normal cells [12]. This indicates 
that CLL cells might be in an anergic state. CLL cells also express signs of constitutive 
changes in signaling molecules consistent with anergy [13, 55, 56]. This might explain why 
CLL cells appear largely unresponsive to stimulation irrespective of membrane Ig 
expression level [12]. However, circulating CLL cells generally express low levels of sIgM 
and sIgD. The features of anergy are more evident in cases with mutated IGHV genes. In 
this group sIgM expression is particularly low and is less responsive to triggering and the 
generated signal downstream the BCR is rather weak [55, 57]. In contrast, cases carrying 
unmutated IGHV genes have a higher sIgM expression and their poly-reactive BCRs are 
more responsive to triggering resulting in activation of robust intracellular signaling [57, 58]. 
There are also differences in basal signaling between the two CLL subgroups with a higher 
signaling in cells with mutated IGHV genes [12]. This difference may be due to a more 
efficient route to anergy in mutated CLL compared to the unmutated [12, 57]. The 
predominant response to BCR signaling in CLL being anergy might explain its generally 
chronic nature, characterized by a reduced apoptosis rather than a high proliferation, and 
the differences associated with mutational status suggest an association between more 
anergy and a favorable outcome [13, 55, 56]. 
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In normal B cells, a chronic exposure to antigen leads to selective downregulation of 
sIgM [47]. This downregulation is dependent on continual antigen binding and is reversible 
following antigen removal. The precise mechanism triggering BCR activation in CLL, 
whether it is antigen dependent or autonomous, remains controversial as described above. 
However, exposure to antigen in proliferative centers (PCs) downregulates expression of 
sIgM, but not sIgD (a known feature of anergy) [57], and this together with local chemokine, 
downmodulate other receptors, such as CXCR4, leading to the exit of CLL cells into the 
blood. In the absence of stimulation there is a recovery of expression of both sIgM and 
CXCR4 which primes the cells for re-entry into tissues and antigen restimulation in further 
rounds [57]. The downregulation is dependent on the BCR signal strength where low level 
BCR engagement may enhance migration allowing the tumor cell to “search” for tissues 
rich in antigens where subsequent high-level BCR engagement inhibits migration allowing 
cells to effectively engage upon supporting interactions. However, a minor fraction of cells 
have been shown to express relatively high levels of sIgM and CXCR4 together with strong 
inducible anti-IgM signaling responses [59]. These cells seem primed for re-entry into tissues 
and for antigen response and might be particularly dangerous. 
The downregulatory changes of sIgM after BCR stimulation and/or the rate of recovery 
in peripheral blood also differ depending on mutational status. Cases with unmutated IGHV 
genes are less sIgM downregulated [58] or maybe they recover more rapidly compared to 
mutated so that the balance point of expression of both sIgM and CXCR4 is higher than in 
cells with mutated IGHV gene [47]. 
The dominant fraction of the CLL clone (> 99%) is in a resting (G0) state of the cell 
cycle [60]. Even though most of these cells appear to be anergic and overexpress the 
apoptosis-inducing BIM, they are protected from death. This is probably due to the 
expression of the anti-IgM inducible, survival-promoting MCL1 protein and over-
expression of BCL-2 whose principal function is to neutralize BIM [47]. CLL cells are 
highly dependent on the BCL-2 overexpression for survival which is supported by their 
sensitiveness to BCL antagonists [61] (see 3.2.3). BCL-2 overexpression also appears to be 
one mechanism by which CLL cells mitigate their requirements for B-cell activating factor 
of the tumor necrosis factor (TNF) family (BAFF). In summary, an unbalanced expression 
of pro and antiapoptotic molecules contributes to extended survival on anergic CLL cells.  
Even though anergy may be the predominant response to BCR signaling there is a 
proliferative fraction in all CLL patients [45, 62]. Exposure of CLL cells to either foreign or 
autoantigen occurs most probably in lymphoid tissues and GEP studies demonstrated that 
BCR signaling is the key regulatory pathway activated in CLL cells in lymph nodes [63].  
BCR associated pathways in CLL cells also show enhanced activation [63] with 
constitutively up-regulated LYN, SYK and BTK kinases [50, 64, 65] as well as the downstream 
effector molecules such as MYC [63]. This enhanced BCR activation was higher in cases 
with unmutated IGHV genes compared to the mutated cases whose activation was more 
heterogeneous [63]. A recent study noted a decrease in Ki67 (a marker of proliferation) 
positivity together with a reduced activity of BTK, PLCγ, ERK and AKT pathways which 
underscores the importance of BCR signaling-controlled cell proliferation in CLL [45]. The 
same study also supports the key role of cell proliferation in CLL and demonstrated that 
blocking cell proliferation via inhibition of BCR signaling is associated with clinical 
responses at the same time frame [45]. 
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Although anergy may appear less dangerous than proliferation one has to bear in mind 
that this state is reversible. Therefore anergic CLL cells cannot be assumed to be harmless. 
The balance between signaling leading to proliferation/survival and anergy and the 
proportion of CLL cells undergoing these distinct responses appears to determine the 
behavior of the disease. This assumption is illustrated by the prognosis differences related 
to mutational status where markers of anergy are more prominent in mutated- whereas 
markers of positive signaling are associated with unmutated IGHV genes. 
In conclusion, signaling through BCR is a key factor for both CLL survival and 
proliferation. This statement is supported by the shown efficacy downstream inhibition [43, 
66]. The pathway complexity and the multiple cross-talk mechanisms with other pathways 
suggest several options for targeted inhibition. 
1.5.2 PI3K/AKT pathway 
PI3Ks are divided into 3 classes where class I contains four catalytic isoforms (α, β, γ, δ) 
which differ in their tissue expression. PI3Kδ is restricted to hematopoietic cells and is 
highly expressed in lymphoid cells where it plays a critical role in B-cell homeostatsis and 
function [48]. The PI3Ks integrate and transmit signals from surface molecules, such as the 
BCR, but also from chemokine receptors (CXCR4) and adhesion molecules (CD40), 
thereby regulating the cell’s growth, survival and migration. The most important outcome 
of PI3K activation is AKT signaling. Activated AKT phosphorylates proapoptotic proteins 
thereby promoting proliferation and survival [48]. In addition, PI3Kδ also activates 
mammalian target of rapamycin (mTOR) [67]. mTOR acts as a mediator of BCR signaling 
as well as a cell cycle regulator from G1 to S phase. PI3K is constitutively activated in CLL 
cells and the PI3K/AKT pathway appears to play a key role in CLL proliferation [66]. Recent 
data show that micro-RNA-22 (miR-22), overexpressed in CLL proliferating cells, maybe 
switch on the PI3K/AKT pathway by lowering phosphatase and tensin homolog (PTEN) 
expression [68]. PTEN is the main negative regulator of the PI3K/AKT pathway. When 
PTEN suppresses AKT activity genes promoting cell cycle arrest are upregulated [68]. Upon 
interactions between CLL cell and microenvironment engagement of CD40 induces 
overexpression of miR-22, which lowers PTEN, which in turns activates AKT resulting in 
inhibition of apoptotic mechanisms, upregulation of survivin (an inhibitor of apoptosis) and 
CLL proliferation through the NFκB pathway [68]. 
In summary, the PI3K/AKT pathway has a key role in CLL and the importance is 
underlined by the clinical effects of PI3K δ inhibitors [66]. 
1.5.3 NFκB pathway 
NFκB transcription factors play an important role in proliferation, class-switching and 
survival in B lymphocytes. NFκB is a dimeric transcription factor normally kept inactive in 
the cytoplasm by interaction with inhibitors called IκBs. Activation is achieved through 
either the canonical or non-canonical pathways (Figure 1) [69]. The canonical pathway 
represents activation through antigen binding the BCR [42]. When BTK, PI3K or AKT is 
stimulated the IκB kinase causes phosphorylation and subsequent proteasomal degradation 
of IκB (the inhibitor of NFκB) allowing NFκB to translocate to the nucleus for gene 
transcription [43]. In the non-canonical pathway activated receptors, such as CD40 recruit a 
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protein complex, which negatively regulates mitogen-activated protein kinase 14 
(MAP3K14), the central activator of NFκB in this pathway. 
NFκB activation provides prosurvival signals to the CLL cells through dysregulation 
of several genes that regulate cell proliferation and survival (BCL-2, MYC) as well as 
aberrant expression of cytokines that regulate growth and proliferation (IL-6, CD40L) [69, 
70]. Activation of the NFκB pathway is regarded as a mechanism of resistance to disease 
eradication in CLL as it is correlated with enhanced fludarabine resistance of CLL cells and 
poorer outcome [63]. 
1.5.4 Toll like receptor 
Innate stimulation of normal B cells includes stimulation of toll-like receptors (TLRs). 
Upon ligand binding of TLR, receptor-specific adapters are recruited and induce a potent 
activation of the canonical NFκB pathway (Figure 1) [69]. Little is known about the 
repertoire and function of these receptors in CLL. However, activation of TLR promotes 
proliferation in CLL cells and protects them from spontaneous apoptosis [71] Some TLRs 
(TLR7 and TLR9) are believed to co-work with BCR in response to autoantigens. The TLR 
expression repertoire does not appear to be influenced by disease stage or mutational status 
but resembles the pattern found in antigen experienced B-cells [71]. MYD88 (myeloid 
differentiation primary response 88) protein is included in this adaptor complex and 
mutations of MYD88 seem to be enriched in IGHV mutated CLL supporting the idea that 
different molecular mechanisms might be implicated in the development of mutated and 
unmutated IGHV CLL respectively [72]. 
1.5.5 MAPK pathway 
Beyond being a part in the downstream signaling activating NFκB, SYK activation leads to 
downstream activation of MAPK (Figure 1) [42]. This pathway regulates a number of 
transcription factors such as the antiapoptotic proteins ERK1/ERK2 and MYC, important 
for proliferation and cell survival [43]. ERK1/ERK2 is constitutively phosphorylated in CLL 
and ERK1/ERK2 dependent induction of MYC might be important to CLL survival and 
proliferation [51]. 
1.5.6 WNT and ROR-1 pathways 
WNTs are a family of glycoproteins with crucial roles in the regulation of proliferation, 
survival and migration of normal cells. Aberrant WNT signaling has been shown in many 
cancers. There are two WNT pathways, the canonical, dependent on varies forms of β-
catenin, and the non-canonical which is β-catenin independent and regulates subsequent 
pathways associated with migration and cell polarity [73]. In CLL the WNT pathway, as a 
set, has shown a high mutation frequency although no individual gene has been 
significantly more involved [74]. The precise mechanisms by which a WNT stimulates the 
cellular responses through these pathways are not fully elucidated but probably involve 
distinct WNT receptors [73]. 
ROR-1 (receptor tyrosine-kinase-like orphan receptor family member 1) is a highly 
conserved receptor tyrosine kinase. The expression varies during embryogenesis but is 
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tightly downregulated after birth. Data indicates that RORs function as receptors in the 
noncanonical WNT pathway where RORs bind WNT regulatory proteins as ligands. ROR-
1 is overexpressed and constitutively phosphorylated in CLL cells. WNT5a has been 
suggested to be a ligand for ROR-1 in tumor cells and they may physically interact with 
each other and activate NFκB [75]. WNT5a also seemed to maintain phosphorylation of 
ROR-1 and a significant correlation between disease activity and phosphorylation intensity 
of ROR-1 where a higher level of phosphorylation correlated with progressive CLL has 
been shown [75]. Targeting ROR-1 in vitro has resulted in selective apoptosis in CLL cells 
and therefore it might be an interesting clinical target. However, more data on ROR-1 and 
its significance in micorenvironmental interaction and intracellular signaling is warranted 
to advance clinical development. 
1.6 Genomic aberrations, gene mutations and micro RNA 
Genomic alterations are thought to constitute the basis for leukemic transformations and the 
variable clinical course of CLL is driven, at least partly, by the immunogenetic and 
molecular heterogeneity of the disease [76]. Genomic aberrations as assessed by fluorescence 
in situ hybridization (FISH) are present in more than 80% of cases [76]. The distinct 
prognostic implications of these aberrations suggest that each abnormality may reflect a 
distinct pathogenesis. At diagnosis a small proportion of patients have a high number of 
genomic aberrations but aberrations may accumulate during the course and lead to a more 
complex karyotype in the relapsed/refractory situation. 
Deletion of 13q is the most common aberration at diagnosis presented as a sole 
abnormality in 35-45% [76].The function of at least one of the deleted genes is down-
regulation of the anti-apoptotic gene BCL-2 which may lead to an increased anti-apoptotic 
resistance [77]. Deletions of 13q vary markedly in size where larger aberrations are 
associated with a poorer prognosis [78]. 
Trisomy 12 is detected in 11-16% of the patients at diagnosis and does not increase at 
relapse or in refractory patients, possibly due to good response to treatment [77].  
11q deletion is identified in 10-17% of patients with CLL at diagnosis. It is usually a 
mono-allelic deletion which includes the ATM (ataxia telangiectasia-mutated) gene. This 
tumor suppressor gene activates p53 and augments the DNA damage response. 11q 
deletion itself does not always result in mono- or biallelic silencing of ATM but is also 
associated with mutated ATM [79], unmutated IGHV genes and poor outcome [76]. ATM 
mutations in the absence of 11 q deletion is rarer compared with 11q deletion [79]. 
The presence of 17p deletion (including loss of the TP53 gene) is predictive of the 
worst prognosis in CLL. The TP53 gene induces cell cycle arrest and promotes DNA repair 
or apoptosis in case of DNA damage and is therefore a key regulator of the cell cycle [74, 80]. 
At diagnosis 17p deletion can only be detected in less than 3-7% of patients [76, 81] but the 
frequency increases up to about 1/3 in refractory CLL [82]. Deletions of 17p coincide with 
TP53 mutations in the residual TP53 allele in high frequency (80%), resulting in 
homozygous p53 inactivation, and patients displaying 17p deletion often harbor other poor-
prognostic markers as well [74, 80, 83]. The frequency of TP53 mutations in the absence of 17p 
deletion is much lower, 4-5% in the untreated setting  [80] but increases with time  up to 
about 18% in the refractory setting [84]. Mutated TP53 has been associated to unmutated 
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IGHV status [85, 86] and a significant proportion of TP53 mutated cases carries mutations in 
other genes as well. The genomic complexity associated with 17p and 11q deletions is most 
probably due to the fact that they have severely impaired cell repair capacity and thereby 
more easily acquire additional aberrations [77]. 
 
The genetic lesions identified by FISH do not fully recapitulate the molecular pathogenesis 
of CLL, nor do they entirely explain the development of chemorefractoriness. Massively 
parallel sequencing technology has provided the discovery of a range of mutated genes 
with well-established roles that underlie CLL. This allowed the reconstruction of genetic 
pathways in disease pathogenesis, such as the cell-cycle control for TP53, and clinically 
important features of CLL. Even though NFκB signaling is generally viewed as a 
consequence of microenvironmental interactions, it may also be activated through 
molecular lesions affecting genes in the pathways maybe making CLL cells independent 
from the microenvironment (Figure 1). A set of genes where mutations are associated with 
tumor genesis (“driver” mutations) have showed associations with standard prognostic 
markers suggesting that particular combinations of genetic alterations may act in concert to 
drive CLL development. 
Besides TP53, the most extensively studied genes are NOTCH1 (Notch homolog1, 
translocation-associated) and SF3B1 (splicing factor 3B subunit 1) and they also seem to be 
the most frequently mutated ones [72, 87, 88]. Mutated NOTCH1 is detected in approximately 
5-20% of patients with increasing frequencies in advanced disease stages [72, 85, 87-90]. 
Mutations which are primarily a 2-bp deletion, generate a premature stop codon which 
results in a constitutively active NOTCH1 [74, 87, 88] and further enhanced NFκB signaling, 
increased CLL cell survival and resistance to apoptosis [77, 88]. Mutated NOTCH1 has been 
associated with unmutated IGHV [74, 85-88, 90] and trisomy 12 [74, 83, 85, 86, 91] but nearly 
exclusiveness of SF3B1 mutation [83, 86] and isolated 13q deletion [85]. There is probably an 
association with TP53 mutation as well [83, 86]. NOTCH1 mutations have shown to have an 
adverse prognostic impact [86-89] and association with chemorefractoriness and Richter 
transformation even though data on the latter is a bit contradictive [83, 87, 89]. 
The SF3B1 gene encodes a protein included in the spliceosome machinery. SF3B1 
regulates a splicing program of genes controlling cell-cycle progression and apoptosis. 
Mutations, primarily located within three hotspot exons [72, 91] may cause functional changes 
in the RNA splicing [74]. Aberrant splicing might be specific for neoplastic development in 
CLL since SF3B1 mutations were not found in other lymphoid malignancies [72]. SF3B1 
mutations are present at 3-10% in newly diagnosed CLL but, maybe due to a subclonal 
selection, appear to increase over time with a frequency up to 20% in relapsed/refractory 
setting [72, 74, 85, 90-92]. The impact of SF3B1 as an important driver mutation in CLL 
development is strongly supported by the clustering in evolutionarily conserved hotspots 
and the fact that mutated SF3B1 appears to be an independent factor for more rapid disease 
progression [83]. SF3B1 is associated with advanced clinical stage and 11q deletion [74, 85, 86] 
as well as other negative prognostic markers such as unmutated IGHV status, TP53 
mutation, CD38 positivity, absence of trisomy 12 and NOTCH1 mutation [72, 74, 83, 86]. 
Patients primarily refractory to fludarabine showed a high percentage of SF3B1 mutations 
[92] but in Richter transformation though, SF3B1 mutations seem to play a minor role [92]. 
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BIRC3 (Baculoviral IAP Repeat Containing 3 gene) encodes a member of the inhibitor 
of apoptosis protein (IAP) family which negatively regulates the non-canonical NFκB 
pathway through inhibition of the central activator MAP3K14 (Figure 1) [69]. Mutation of 
BIRC3 leads to a constitutive activation of NFκB signaling. The BIRC3 locus is located 
close to the ATM locus on 11q [93, 94] and mutations, mainly described as deletions or 
insertions, are selectively restricted to CLL [94]. Approximately 4% of the CLL patients 
display mutated BIRC3 at diagnosis [93, 94] but mutations may emerge over time [79, 93, 94] to a 
frequency of 24% in the refractory setting maybe due to a clonal selection prior to 
treatment [94]. There is a high incidence of BIRC3 mutations in cases with 11q deletion and 
a lack of BIRC3 mutations in the absence of ATM mutations [79]. In contrast BIRC3 
mutations tend to distribute in a mutually exclusive fashion with TP53 mutation [94]and 
IGHV mutated CLL [85, 94]. BIRC3 mutations have been associated with fludarabine 
refractoriness [93, 94] being present in approximately 40% of fludarabine refractory CLL with 
TP53 wild-type [94]. BIRC3 mutation may therefore represent a large fraction of the chemo-
resistant cases with wild-type TP53. 
Various other recurrent mutations have been reported at frequencies below 10% [86, 88]. 
As data in CLL are limited their impact remains elusive. MYD88 is such a mutation, coding 
for a critical adaptor molecule of the TLR signaling pathway (Figure 1). Mutations have 
been described as single nucleotide change, activating mutations of the NFκB pathway [74, 
88]. Mutations of MYD 88 are associated with sole deletion 13q [74, 85, 86]and with mutated 
IGHV status [74, 86-88] but with no other concurrent mutations [85].  
The increased TP53 mutation in NOTCH1 and SF3B1 mutated subgroups might 
indicate cooperating effects and the exclusivity of NOTCH1 mutations and SF3B1 
mutations might indicate different pathogenic mechanisms and possibly distinct classes of 
driver mutations [83]. Larger studies are required to unravel the relative impact on co-
localized mutations and deletions such as ATM- and BIRC3 mutation and 11q deletion. In 
conclusion, associations between different mutations and other biomarkers are currently not 
fully explained clear and remain to be further investigated. 
 
MicroRNAs (miRNAs) are small noncoding RNAs that encode tiny transcripts regulating 
the expression of multiple target genes. Mature miRNAs are loaded into the RNA-induced 
silencing complex which bounds to mRNA making it untranslated or degraded [95]. The 
extensive dysregulation of miRNA expression in CLL might contribute to the pathogenesis. 
Deletion 13q harbors miRNAs (miR-15a/16-1) that are negative regulators of BCL-2 [95]. 
The negative regulation of BCL-2 by these miRNAs might be a key mechanism in the CLL 
pathogenesis. Deletion of miR-15a/16-1 is inversely correlated with the expression of  
BCL-2 and deletion of miR-15a/16-1 appears to promote CLL in humans [95]. Numerous 
miRNAs with a distinct signature for CLL have been identified. Some are deleted in 
aggressive CLL (miR-34) [95], some seem to activate important pathways (miR-22 and 
PI3K/AKT pathway) [68] and others are suggested a role in an indolent clinical course  
(miR-29a) [95]. The mechanisms that cause aberrant miRNA transcriptional control are not 
completely clear. However, there is increasing evidence that epigenetic mechanisms play a 
role in the changes in regulation of miRNA transcription and promoters of some miRNAs 
have shown consistent hyper- or hypomethylation in CLL [96]. 
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1.7 Epigenetic alterations 
The importance of epigenetic control in tumor suppression is underscored by the recent 
discoveries of mutations in known epigenetic regulatory genes in human cancers [97]. 
Epigenetic mechanisms control the transcriptional availability of various parts of the 
genome through chromatin marking and packaging thus allowing genetically identical cells 
to achieve diverse stable phenotypes [97]. Epigenetic states can be stably maintained and 
persist through multiple cell divisions yet they can adapt to changing developmental or 
environmental needs and may exert powerful effects on cellular phenotype. Most probably 
these epigenetic changes cooperate with genetic mutations to mold tumor evolution [97]. 
The best-studied epigenetic modification is cytosine-phosphoguanine dinucleotide 
(CpG) methylation where methyl groups are added to CpG sites and regulate gene 
expression. The profile of CpG methylation differs among the prognostic subgroups of 
CLL. Genes involved in these aberrantly methylated loci are those involved in CLL 
pathogenesis (BCL-2, ZAP70 (zeta associated protein 70) and NOTCH-1) as well as gene 
regulators and pathways involved in B cell signaling [98]. For example DNA methylation 
might have a role in regulating the expression of the integrin CD49d, where lack of 
methylated CpG was associated with CD49d expression [46]. One study was able to 
categorize patients into three distinct subgroups with differences in clinical outcome 
depending on methylation profile. In line with previous findings, unmutated IGHV genes 
were strongly related to naïve B cells and mutated IGHV genes aligned with mature B cells 
with a better outcome for the latter [99]. This suggests a methylation imprint corresponding 
to the putative cell of origin. The third subgroup consisted of mainly mutated IGHV genes 
but with a methylation signature more similar to naïve B cells and showed an intermediate 
clinical outcome [99]. It appears as differences in methylation patterns occur over time but 
not in absence of genetic changes which suggests a temporal hierarchy in which genetic 
alteration precede marked epigenetic changes [98]. In addition to DNA methylation, other 
epigenetic marks undergo broad changes, e.g. several miRNA promoters are aberrantly 
methylated which may affect the expression of miRNAs [96]. The epigenetic observations 
highlight the complex relationship between genetic and epigenetic features in CLL. 
1.8 Microenvironment 
CLL cells rapidly undergo apoptosis when removed from patients but this may be 
prevented by adding cytokines or other cell types [100] indicating that CLL cells are highly 
dependent on external stimuli for proliferation and survival.  
New data point out lymph nodes as the predominant site for proliferation where 
exposure of CLL cells to either foreign or autoantigen probably occurs [63]. Besides BCR 
signaling, the tumor microenvironment that exists in the lymph nodes and bone marrow is 
important for CLL cell survival. The proliferation occurs within microanatomical tissue 
sites known as proliferation centers (PC). PC, also called pseudofollicles, is a hallmark 
histopathology finding in CLL and exist in the bone marrow and lymph nodes, where 
tumor cells interact with antigen and also have close contact to a host of accessory cells. 
These cells consist of mesenchymal stromal cells (MSC), monocyte-derived nurse-like 
cells (NLC) as well as T cells [42, 48].  
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The processes of extravasation and migration of CLL cells into secondary lymphoid 
tissues are mediated by adhesion molecules where circulating CLL cells interact transiently 
and reversibly with vascular endothelium through integrins (rolling). Integrins are 
heterodimeric glycoproteins which mediate cell-cell and cell-matrix adhesion. The α4β1 
integrin CD49d (VLA-4) is a receptor for VCAM-1 and fibronectin which is expressed on 
cytokine-activated endothelium [48]. CD49d appears to be functionally linked to the 
chemokine receptor CXCR4, where triggering of CXCR4 upregulates the CD49d-VCAM-
1 adhesion making a firm adhesion between CLL cells and stromal cells [46, 48]. In addition, 
CD49d seems to be functionally linked to the co-receptor CD38 where CD49d + cells 
overexpress chemokine C-C motif ligand 3 and 4 (CCL3/4)) upon CD38 triggering [46, 101]. 
High levels of CD49d and CD38 in CLL cells are associated with a higher migratory 
potential towards CXCL12 chemokine [42]. CD38, binding to CD31 on endothelial cells and 
NLC, also appears to potentiate a more efficient adhesion of CD49d+ cells [42, 46]. CLL cells 
have a high affinity for bone marrow stromal cells (BMSC) in vitro [100]. This firm adhesion 
favors upregulation of antiapoptotic proteins (BCL-2) and proto-oncogenes through 
PI3K/AKT or NFκB signaling in vitro and the firmer adhesion the stronger the signal to the 
antiapoptotic machinery [46, 48]. In conclusion, the integrin CD49d acts in a complex 
interplay with other surface receptors on CLL cells. The important role of integrins is 
underlined by the possibility to inhibit their function with the BTK inhibitor ibrutinib [48] 
and that expression of CD49d appears to have a significant prognostic impact [102]. 
After adhesion, chemokine gradients guide the CLL cells into the tissue, a process 
referred to as homing [48]. The CXCR4- CXCL12 axis appears to be a key pathway of CLL-
microenvironment cross-talk where stromal cells in secondary lymphatic tissues attract 
CLL cells via secretion of chemokines of which CXCL12 is the most prominent. The 
chemokine receptor CXCR4 is highly expressed on CLL cells in peripheral blood which 
allow CLL cells to sense and follow levels of chemokine CXCL12, secreted by 
mesenchymal stromal cells, mediating chemotaxis and migration [103]. The surface 
expression of CXCR4 is normally downregulated by high levels of CXCL12 [103], 
proliferation and BCR signaling, all being present in tissues [48]. Stimulation of CXCR4 
activates downstream pathways (PI3K and MAPK) providing a pro-survival effect [104]. 
High CXCR4 expression in CLL blood cells has been associated with an increased risk for 
organ infiltration and poorer outcome [105]. In conclusion, CXCR4 signaling appears to 
attract malignant cells as well as promote their survival. These effects can be inhibited by 
PI3K- [67], BTK- [50] and SYK [106] inhibitors leading to apoptosis as well as impaired 
migration of CLL cells. 
Activated CLL cells also express and secrete CCL3/4, which are chemoattractants for 
monocytes and T cells, in response to BCR signaling [107]. Elevated plasma level of CCL3/4 
has been associated with poor outcome [108]. The production CCL3/4 may partly explain the 
increased numbers of T cells in PC and this might be a way for CLL cells to induce 
trafficking and homing of accessory cells in the microenvironment, in particular T cells and 
monocytes [107, 108]. 
In addition to mediate chemotaxis, BMSCs seem to activate CLL cells by a prominent 
upregulation of the lymphoid proto-oncogene TCL1(T-cell leukemia/lymphoma protein 1) 
and BMSCs which in turn appear to be activated by the CLL cells via expression of protein 
kinase C and subsequent activation of NFκB in BMSCs [48]. 
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NLC can be found in the spleen and lymphoid tissues. The mechanism through which 
NLC differentiate from blood monocytes is not completely clear but CLL cells appear to 
stimulate NLC differentiation in vitro by activating for example TLR-9 [42]. NLC attract 
CLL cells by secreting CXCL12 and CXCL13 and confine them in close contact via 
transmembrane chemokine receptors (CXCR4 and CXCR5). CXCL12 also acts as a co-
stimulatory factor for the CD4+ T cells in CLL [109]. NLC activate the BCR signaling 
cascade in CLL cells confirmed by a GEP analysis showing characteristic induction of 
genes in the BCR and NFκB pathway [107]. In addition, NLC activate CLL cells via BAFF 
and a proliferation-inducing ligand (APRIL) which over-rides the pro-apoptotic function of 
BCL-2, thereby promoting survival and proliferation [47, 48]. Finally, NLC express CD31 
which stimulates survival when binding CD38 on CLL cells [42]. 
In addition to antigen engagement, CD40L and cytokines (IL-4) provided by CD4+ T 
cells are critical for proliferation and survival in normal B cells by activating the NFκB 
pathway [42]. In PC there are an increased number of CD4+ T cells in close proximity to 
dividing malignant cells [110]. This might be due to chemokines (CCL3/4) secreted by CLL 
cells as a consequence of BCR signaling after NLC stimulation. These CD4+ T cells 
express CD40L [47, 48]. Recent data suggest that CD40-CD40L binding might induce 
activation of the PI3K pathway promoting survival and proliferation in CLL cells [68]. In 
summary, CD4+T cells appear to provide positive regulatory signals to CLL cells within 
tissue. In addition cytotoxic CD8+ T cells do not only have poor killing due to unfunctional 
immune synapses but also have an increased production of factors that might protect CLL 
cells from apoptosis [109]. 
 
Figure 2. The CLL microenvironment.
 
A) In the CLL microenvironment, CLL cells interact 
with bone marrow stromal cells (BMSC) and nurse 
like cells (NLC) through adhesion molecules and 
chemokine receptors, expressed on CLL cells. These 
interactions, in addition to B-cell receptor 
engagement, promote CLL survival, proliferation, 
and homing to tissues. 
 
B) CD4+ T cells are recruited into the tissue 
microenvironment by CLL cell–derived chemokines, 
including CCL3 and CCL4, to support CLL cell survival 
and proliferation. Inhibitory receptors expressed by CLL 
cells induce defective immune synapse formation 
between CLL and T cells. Cytotoxic granule secretion 
by CD8+ T cells is also defective, and production of 
soluble factors by CLL cells suppresses NK cell 
cytotoxicity, favoring immune evasion of CLL cells. 
Reprinted from Clin Cancer Res 2014;20:548-556, ten Hacken E, Burger JA, Molecular Pathways: Targeting the Microenvironment 
in Chronic Lymphocytic Leukemia - Focus on the B-Cell Receptor, with permission from AACR. 
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In summary, there are several ways to activate the NFκB pathway in the lymphoid 
microenvironment including BCR signaling, TLR and CD40 stimulation (Figure 2A) [49]. 
The overall mix of chemokines contributes to co-localization of stromal cells, NLCs and 
activated CD4+ T cells. This altogether provides a niche favorable for CLL cell survival 
which keeps them away from immuno-chemotherapy resulting in drug resistance and 
disease persistence (Figure 2B) [48, 109, 111]. Agents inhibiting BCR downstream signaling 
induce a transient lymphocytosis indicating interplay between the BCR and tissue-homing 
events. The clinical effectiveness of these inhibitors provides compelling evidence for the 
importance of tissue-based antigen stimulation in CLL. Disruption of cross-talk in the 
microenvironment is an attractive novel strategy for treatment. Thus there is striking 
evidence that the neoplastic B-cells co-evolve together with a supportive tissue 
microenvironment which promotes the CLL cell survival, growth and drug-resistance. 
1.9 Diagnosis, clinical staging and manifestations 
CLL is defined by the World Health Organization [112] as a leukemic lymphocytic 
lymphoma which differs from small lymphocytic lymphoma (SLL) by its leukemic 
appearance. The diagnosis is set by analysis of blood count, blood smear and immune 
phenotype from a blood sample. The presence of more than or equal to 5x109/L  
B lymphocytes in the peripheral blood is required [113]. The blood smear shows 
characteristically small, morphologically mature lymphocytes. The clonality and phenotype 
of the B lymphocytes need to be confirmed by flow cytometry. The CLL cells have weak 
sIg levels and co-express the T-cell antigen CD5, and the B-cell surface antigens CD19, 
CD20 and CD23. I contrast to normal B cells, the levels of CD20 and CD79b are 
characteristically low and CLL cells are usually negative for cyclin D1 and CD10. Each 
clone of leukemia cells is restricted to expression of either κ or λ light chains [114]. 
A bone marrow aspirate or biopsy is not required at diagnosis but is recommended in 
cases with cytopenia to distinguish whether it is of autoimmune cause or due to massive 
bone marrow infiltration. A bone marrow analysis is also recommended before initiating 
treatment [113]. 
Despite a common diagnostic immunophenotype CLL is characterized by extensive 
clinical heterogeneity. The classical staging systems according to Rai [115] or Binet [116] rely 
on physical examination and standard laboratory tests and identify 3 patient subgroups with 
distinct clinical outcomes.  
Most patients are asymptomatic at diagnosis and are diagnosed incidentally while 
undergoing routine blood tests. Common symptoms include painless lymph node swelling, 
hepatosplenomegaly, constitutional symptoms and symptoms related to bone marrow 
failure [113, 115-117]. Patients may also suffer from recurrent infections and autoimmune 
complications [1]. 
1.9.1 Autoimmune complications 
CLL is associated with autoimmune manifestations, both hematological, which are the 
most common, and non-hematological [118]. Epidemiological data on incidence and 
prevalence are limited but the overall risk of autoimmune disorders is estimated to be in the 
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range of 5 to 10% [119]. Examples of non-hematological autoimmune complications are 
paraneoplastic pemphigus, acquired angioedema and glomerulonephritis. These are very 
rare and will not be discussed further in this text. 
The most common autoimmune complication is autoimmune hemolytic anemia 
(AIHA) reported in about 7% of CLL patients [120]. The second most common complication 
is autoimmune thrombocytopenia (ITP) reported in 2-3% of the patients. Autoimmune 
neutropenia and pure red cell aplasia are rare complications (< 1%) [120]. Cytopenias 
complicating CLL are classified into two groups: “simple” (stable CLL disease) and 
“complex” (concomitant CLL progression). The autoimmune cytopenias are particularly 
common in advanced disease but may occur at any clinical stage [120]. 
The underlying mechanisms for the development of autoimmune complications are 
only partially understood. In AHIA and ITP polyclonal, high-affinity IgG autoantibodies, 
produced by nonmalignant B-cells via a T-cell mediated mechanism attach and destroy the 
patient’s own erythrocytes and platelets. The CLL cells seem to act as antigen-presenting 
cells, presenting peptides that are identified as foreign by helper T cells. The autoantibody-
opsonized cells are subsequently destroyed via antibody dependent cytotoxicity (ADCC) or 
complement dependent cytotoxicity (CDC) [120]. Diagnosis of AIHA is based on laboratory 
features (LDH, DAT (direct antiglobulin test), haptoglobin, reticulocytes, and bilirubin). 
There are two main types, the warm (90%) and the cold (10%) type, where antibodies 
destruct the erythrocytes at normal and below normal body temperature respectively [120]. 
In ITP the diagnosis is in most cases based on a comprehensive evaluation of clinical 
findings such as a rapid, “unexplained” fall in platelet levels and rising levels after steroid 
or immunoglobulin treatment, absence of splenomegaly and an augmented megacaryocytes 
in the bone marrow [121]. AIHA and ITP may present together, a combination termed Evans 
syndrome [119, 120]. Some poor prognostic factors such as unmutated IGHV gene and ZAP70 
expression have been associated with AIHA and ITP but autoimmune cytopenia does not 
necessarily confer to a poor prognosis [120, 121]. 
However, the most common cause of cytopenia is bone marrow failure (54%) and 
since autoimmune complications are not necessarily equal to advanced disease [119] a bone 
marrow sample is mandatory in order to distinguish autoimmunity from massive bone 
marrow infiltration.  
Steroids are the first treatment option of simple autoimmune cytopenia with a response 
rate up to 80%. However, relapses are common and some patients develop life-threatening 
autoimmune cytopenia that is resistant to treatment [120, 122]. For non-responders or at 
relapse, intravenous immunoglobulins or splenectomy may be considered as second line 
treatment where the latter is more established in ITP. Alternative options for steroid-
refractory autoimmune cytopenia are rituximab, immunosuppression with cyclosporine or 
azathioprine and for ITP thrombopoetin analogues may be an option as well [120]. 
In complex cytopenia, monotherapy with purine analogues and alkylating agents are 
associated with increased risk of severe autoimmune cytopenia but a combination of 
rituximab, cyclophosphamide, vincristine and prednisone or dexamethasone may be an 
option [2]. Single-agent alemtuzumab is effective in complex and therapy-related AIHA [122]. 
Alemtuzumab offers a combination of potent antitumor as well as profound 
immunosuppressive activity which may explain the effect in life-threatening hemolysis. 
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Therefore alemtuzumab may be considered for early use in the complex situation [122]. 
There are only limited data on alemtuzumab treatment against CLL related ITP. 
1.9.2 Immune defects and infections 
CLL cells have created strategies to escape from and to suppress the immune system. 
Immune dysfunction is a key feature of CLL highlighted by the increased susceptibility to 
infections and autoimmune complications. Infections are important causes of morbidity and 
mortality and constitute the major cause of death, in this group of patients. The impairment 
of the immune system may be further aggravated by treatment e.g. fludarabine and 
alemtuzumab [123]. These treatments have introduced a new spectrum of infectious 
complications caused by pathogens such as pneumocystis, listeria, candida and aspergillus 
and CMV. Infection prohylaxis with antimicrobial drugs against herpes virus and 
pneumocystis is routine in combination with alemtuzumab or fludarabine-based 
chemotherapy. Therapy-related immune defects persist after discontinuation of therapy. 
Therefore antimicrobial prophylaxis is continued for several months. 
 
B-cell defects 
Hypogammaglobulinemia is present in up to 67% of the patients and correlates with the 
duration and stage of the disease. It is an important factor contributing to infection risk in 
CLL and monitoring is recommended [124]. Patients with hypogammaglobulinemia and 
recurrent episodes of serious infections may benefit from immunoglobulin substitution [4, 
125] even though intravenous immunoglobulin does not restore IgM or IgA deficiencies. 
Despite normal Ig levels some patients display reduced levels of IgG subclasses which may 
predispose them for infections. Screening for IgG subclass deficiency might be indicated 
for patients with recurrent infections [124]. The response to vaccines is generally inefficient 
and the more severe hypogammaglobulinemia the weaker vaccine response [126]. The 
mechanism underlying the development of hypogammaglobulinemia is not completely 
understood. The number of normal B lymphocytes is usually reduced maybe due to the 
decreased T-cell helper function and an excessive T cell suppression. A skewed cytokine 
production from T cells might also contribute. CLL T cells produce IL-4 which promotes 
upregulation of CD30. Upon CD30- CD30L binding the sensitivity to FasL-mediated cell 
death is increased and class-switching is impaired in non-malignant B cells [109]. In addition 
to hypogammaglobulinemia, CLL B cells have reduced expression of CD80 and CD86 and 
are functionally poor at antigen presentation. Even though CLL cells may respond to BCR 
triggering the overall picture is of extensive anergy [57]. 
 
T-cell defects 
The T cell compartment is highly abnormal in CLL patients with increased total number of 
T-cells in the peripheral blood due to an increase in CD8+ T cells resulting in a fall in the 
CD4/CD8 ratio [48, 109]. In contrast, secondary lymphoid organs and bone marrow show 
increased numbers of CD4+ T cells [110]. 
Despite increased number, the circulating T cells in CLL have an abnormal phenotype 
with upregulation of activation markers (CD69 and HLA-DR) and downregulation of 
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CD28. This phenotype is consistent with chronic stimulation and it remains unclear 
whether this is directly related to CLL or if other factors, such as CMV, are involved [48, 109].  
In addition, genetic T cell receptor studies have demonstrated expansions of clonal and 
oligoclonal T cells with an activated phenotype which provide further evidence of chronic 
activation  [109]. In the normal setting, antigen exposure of naïve CD8+ T cells leads to 
differentiation to memory CD8+ T cells which can persist long term and proliferate rapidly 
at re-infection. In the course of chronic infections, CD8+ T cells become “exhausted” with 
poor effector function and the expression of multiple inhibitory receptors. CLL T cells have 
an increased expression of such inhibitory receptors (CD244, CD160 and PD-1 
(programmed cell death 1)), called exhaustion markers [127]. Exhausted T cells fail to 
establish functional immune synapses which results in defective cytotoxicity and the CD8+ 
T cells become unable to effectively eliminate CLL cells [127]. CLL T cells differ from 
virally exhausted ones in having an increased ability to produce IFNγ and TNFα which can 
protect CLL cells from apoptosis and induce their proliferation [127]. In addition, CLL cells 
produce IL-6 which promotes T cells to produce IL-4 which in turn protects CLL cells 
from apoptosis by modulating levels of BCL-2. Increased IL-4 levels also promote 
upregulation of CD30 on T cells and upon CD30-CD30L interaction there is an increased 
production of IFNγ and TNFα [109]. GEP analyses of CLL T cells have shown profound 
alterations in expression of genes involved in cytoskeletal formation translated into a 
functional defect in filamentous actin polymerization resulting in defective immunological 
synapse formation with antigen presenting cells and in the CD8+ T cells also in impaired 
vesicle trafficking and cytotoxicity [109, 128] . Decreased actin polymerization also contributes 
to impaired integrin migration [109]. Further assays have identified additional receptors 
increased on CLL cells (CD200, CD270, PD-L1 (programmed cell death ligand1)) that 
may induce impaired immunological synapse function in T cells [129]. 
There is also a third-party effect mediated by increased numbers of regulatory 
CD4+CD25+T cells (Treg). The number of Tregs increases with advanced disease. The high 
levels of Tregs might be mediated by increased expression of CD27 and CD200 on CLL 
cells. Tregs express the inhibitory receptor CTLA-4 (cytotoxic T-lymphocyte associated 
antigen-4) and Tregs from CLL patients have increased CTLA-4 expression. Thus it is likely 
that multiple inhibitory signaling axes induce defective T-cell function in CLL [48, 109]. 
 
Other immune defects 
CLL cells downregulate NK-cell function. The mechanism is not known but might include 
soluble factors and/or direct contact with expression of certain molecules. This results in a 
functional defect with a lack of cytoplasmic granules and a reduced ability to lyse leukemia 
cell lines. NK cells also experience an impaired immunological synapse formation due to a 
defective actin polymerization. 
NK-cells from patients with CLL had lower cytolytic capacity than those from MBL 
patients. Further, in later stages of CLL as well as in those with unmutated IGHV genes it 
was shown that NK cell numbers were decreased [48, 109]. 
There is some evidence for defects in monocyte and neutrophil function in CLL as well 
but this field is much less explored [109]. 
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1.9.3 Richter syndrome 
Among CLL patients 1-11% will experience transformation into a more aggressive 
lymphoma called Richter syndrome (RS) [130]. The vast majority of these transformations 
are diffuse large B cell lymphoma (DLBCL) but there are rare cases of transformation into 
Hodgkin lymphoma [130]. The median time from CLL diagnosis to RS is 1.8-5 years and 
therefore RS is not always a late event [130]. 
The molecular pathogenesis of RS is not completely understood. Among DLBCL 2 
subgroups have been identified, those clonally related to CLL (80%) and those clonally 
unrelated to the underlying CLL (20%) [130]. The median overall survival (OS) differed 
significantly between these groups where patients with clonally unrelated RS representing 
de novo DLBCL had a better prognosis with a median survival of 5 years. In contrast, the 
median OS for the clonally related RS was approximately 1 year [130]. No single lesion or 
combination of genetic lesions or cellular pathways appear to be responsible for CLL 
transformation into RS however > 90% of the cases display combinations of lesions 
suggesting that RS transformation involves general regulators of tumor suppression, cell 
cycle control and cell proliferation rather than specific B cell signaling pathways [131, 132]. 
RS is associated with high risk cytogenetics (17p deletion, 11q deletion) [130, 133]. 
Approximately 60% of cases with RS display TP53 mutations, an independent predictor of 
poor OS [133]. The second most frequent aberrations are NOTCH1 and MYC mutations 
occurring in about 30% of the cases each [87, 133]. 
Several RS risk factors have been described. Heritable germline polymorphisms might 
predispose but their functional consequences in RS pathogenesis remain elusive [130]. The 
only clinical features associated with a higher risk of future RS are advanced stage and 
lymph nodes > 3cm on physical examination [134]. Unmutated IGHV status is associated 
with approximately 4-fold risk of RS relative to those with mutated IGHV genes [133, 134] and 
patients with stereotyped BCRs have a higher risk of RS independent of mutational status 
[134]. Conventional CLL therapy, alone or in combination, may be a risk factor but the 
impact remains unclear and little is known about the risk with new targeted therapies [130].  
A single prognostic model for RS is not currently available but studies of a future model 
need to incorporate the clonal relationship together with genetic factors (TP53 disruption, 
mutated NOTCH) and clinical features (performance status, lymph node size) [130]. 
Several signs and symptoms may indicate a possible transformation into RS but these 
may also be due to progressive CLL. They include rapidly enlarging lymph nodes, weight 
loss, high-grade fevers, hypercalcemia and elevated LDH. RS is diagnosed via excisional 
lymph node biopsy. A fine needle aspiration is not sufficient to establish or exclude RS. 
Since not all lymph node sites are affected by RS, the selection of site for biopsy is critical 
and PET-scan might be valuable to identify the most suitable site for biopsy [135]. 
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is 
the standard treatment of DLBCL RS and the response rates are about 50%. Several other 
combinations of chemotherapeutics have been evaluated but so far none has proven more 
effective than R-CHOP. However, randomized clinical trials are lacking. Ibrutinib 
monotherapy does not appear to be enough in RS however combinations with R-CHOP 
might become an option in the future [130]. Allogeneic or autologous stem cell 
transplantation might be an option for patients with limited comorbidities in remission [136]. 
However, few patients achieve adequate response to induction to proceed to transplant [130]. 
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1.10 Prognostic and predictive factors  
The staging systems of Rai [115] and Binet [116] use inexpensive, simple components. They 
have proved useful for estimating outcome since patients Binet A/Rai 0, Binet B/Rai I-II 
and Binet C/Rai III-IV show a median OS of > 10 years, 5-7 years and < 3 years 
respectively [137]. However, both staging systems lack precision in identifying prognostic 
subgroups, have limited ability to predict prognosis for individual patients [138] and provide 
no information on how patients will respond to treatment. Several prognostic biomarkers 
have been identified, some of these also have a predictive value, in order to improve 
discriminatory power and risk stratification. 
1.10.1 Genomic aberrations and gene mutations 
One of the most reliable molecular prognostic markers is the established hierarchical model 
of the prognostic impact of genomic aberrations (Figure 3). 
The presence of 13q14 deletion as a sole abnormality is associated with a more indolent 
disease course [76] as well as a lower risk of transformation [139]. Trisomy 12 is associated 
with a less-favourable prognosis and deletion of 11q is associated with younger age at 
diagnosis, extensive lymphadenopathy, rapid progression and shorter treatment-free and 
overall survival [76]. However, the adverse prognostic significance of 11q deletion may be 
overcome with chemoimmunotherapy [81]. CLL patients with 17p deletions display the 
worst outcome with a rapid progression and short survival [76, 83].  
 
Figure 3. Probability of survival 
from the date of diagnosis among 
patients in the five genetic 
categories.  
The median survival times for the 
groups with 17p deletion, 11q 
deletion, 12q trisomy, normal 
karyotype, and 13q deletion as the sole 
abnormality were 32, 79, 114, 111, 
and 133 months, respectively.  
Reproduced with permission from  
N Engl J Med 2000; 343:1910-1916,  
Döhner H, Genomic Aberrations and  
Survival in Chronic Lymphocytic Leukemia. 
Copywright Massachusetts Medical Society. 
A TP53 mutation is an independent prognostic marker related to short time to treatment, 
short progression free survival (PFS) and  OS regardless of the presence of 17p deletion [80, 
86, 140]. Notably, patients with TP53 mutations carrying a mutated IGHV gene have shown a 
superior survival compared to those with unmutated IGHV. One recent study showed that 
OS for those with mutated CLL did not differ significantly from patients displaying normal 
karyotype/deletion 13q [93]. TP53 disruptions (17p deletion and TP53 mutation) are 
associated with poor response to chemotherapy [80, 83]. The mechanism of action of these 
agents relies on p53 induced cell death [76]. TP53 disruptions are therefore predictive 
17p deletion 
11q deletion 
12q trisomy 
Normal 
13q deletion as sole  
abnormality 
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markers which shall be evaluated before treatment initiation and patients with these 
aberrations should be recommended alternative less p53-dependent treatment alternatives 
[113]. Even subclonal TP53 mutations, not detectable by tests currently used in clinical 
routine, may affect the response and chemotherapy might remove the incumbent clones in 
favor of a more aggressive one [21, 22]. 
NGS studies have pointed out novel genes frequently mutated in CLL [72, 74, 87-89, 92, 94]. 
Mutated ATM is associated with a shorter PFS and OS after first line treatment [141] and 
its presence might subdivide 11q deleted patients into a subgroup with poorer prognosis [79]. 
Mutated NOTCH1 has been associated with both a shorter time to treatment and 
survival [85, 87-91] as well as chemorefractoriness [87, 89]. However, its independent prognostic 
impact is not completely clear. In recent studies, [83, 85, 86] mutated NOTCH1 was not an 
independent prognostic marker for PFS [83], time to treatment or OS [86]. Mutated NOTCH1 
appears to be a predictive marker for decreased benefit from the addition of rituximab to 
FC (fludarabine and cyclophosphamide) [83] and might be a predictive marker for reduced 
benefit from the addition of ofatumumab when added to chlorambucil [142]. However, the 
biological mechanisms underlying these findings remain unclear. 
Mutated SF3B1 is associated with advanced disease and poor prognosis [72, 74, 83, 92] with 
a shorter time to treatment and OS [74, 88, 90-92] independent of other prognostic markers. 
However, in a multivariate analysis mutated SF3B1 was only an independent marker for 
shorter PFS but not for OS [83]. Yet, it was still an independent factor for more rapid disease 
progression. Compared to the impact of the mutations status of the IGHV region the data is 
a bit more elusive [72]. SF3B1 appears, after TP53 mutation and IGHV mutational status, 
among the strongest prognostic markers in patients receiving the current standard first-line 
therapy but has no implication as a predictive marker [83]. 
Mutated BIRC3 is associated with refractoriness to chemotherapy as well as short OS 
similar to that of CLL patients harboring TP53 abnormalities [94]. Its independent effect is 
not definitely clear. Since BIRC3 deletion in 11q deleted CLL tend to co-exist with ATM 
deletion [79, 93, 94] and the outcome for patients with BIRC3 mutations and 11q deletions but 
without ATM mutations is comparable to those with only 11q deletion, ATM mutational 
status might be the most clinically informative genomic lesion in 11q deleted CLL [79]. 
BIRC3 mutations have been associated with fludarabine refractoriness [93, 94] and mutations 
are seen in approximately 40% of fludarabine refractory CLL with TP53 wild-type [94]. 
Therefore BIRC3 mutation may represent a large fraction of chemo-resistant cases with 
wild-type TP53 and might be valuable to include in routine analysis in order to detect cases 
that would not benefit from fludarabine. Further, recent findings in mantel cell lymphoma 
suggest that BIRC3 mutations may predict refractoriness to the BTK inhibitor ibrutinib [143]. 
Mutated MYD88 is associated with 13q deletion and patients harboring both defects 
might have an improved OS compared to wild-type patients [85, 93]. 
The identification of gene mutations has led to refined risk stratification and might help 
to identify patients that need closer follow-up and specific treatment recommendations. The 
influence of gene mutations may also vary according to the type and intensity of the 
regimen administered [83, 90], especially when taking into account that subclonal populations 
might be positively selected by treatments. Detection of tumor cell populations of very low 
clonal abundance might be highly sensitive predictive biomarkers of CLL in the future [22]. 
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1.10.2 IGHV mutational status 
Since stimulation through the BCR plays a preeminent role in CLL cells it is not surprising 
that the mutational status is constantly selected as a relevant prognostic marker [102]. IGHV 
mutational status can be examined by routine tests, is very stable and does not change 
during the course of the disease [26, 77]. Unmutated IGHV is associated with high-risk 
characteristics and shorter time to treatment [144] as well as survival [25, 26, 83, 86, 145]. Mutated 
IGHV cases had significantly superior outcomes compared to unmutated ones that had 
similar outcome to the cases carrying unfavorable genomic aberrations such as TP53 
mutations [85]. This was consistent even in low-/very-low-risk groups with isolated 13q 
deletion and/or no aberrations. However, there is heterogeneity within the IGHV mutated 
group where cases carrying IGHV3-21 genes display a poor outcome [146]. This gene is 
highly skewed in geographical distribution being more frequent in Scandinavia (6.5%) 
compared to other Western countries (2.6-4.1%) [147]. The IGHV mutational status and 
FISH aberrations may have a complementary role in predicting survival in CLL. Since the 
IGHV mutational status might influence the outcome of targeting BCR-associated kinases 
with inhibitory drugs it will perhaps be considered a predictive marker in the future [148]. 
1.10.3 Serum markers 
Lymphocyte doubling time (LDT) is defined as the time in months it takes for the 
lymphocytes to double in absolute number. LDT is an independent prognostic marker [149]. 
A short LDT is related to a more aggressive disease and an LDT < 6 months indicates an 
active disease with treatment indication. A limitation with LDT is its inability to predict 
outcome at an early stage of the disease and the low predictable value. Three serum 
markers are used as prognosticators. LDH may be increased in CLL and a high level 
corresponds to poor prognosis and risk of transformation [77]. Similarly, high level of 
β2microglobulin indicates a more advanced clinical stage with a shorter PFS [77]. Finally, 
high levels of thymidine kinase are associated with a more aggressive disease, unmutated 
IGHV genes, high-risk genomic aberrations and short LDT [77]. Serum markers may have a 
role in CLL prognostication however focus is currently on factors that can provide more 
disease-specific information regarding survival and response to treatment. 
1.10.4 Other prognostic markers 
There is a myriad of molecules suggested as prognostic markers. This text focuses on the 
most relevant and evaluated ones. 
A recent multicenter worldwide analysis showed that expression of CD49d, the α chain 
of the α4 β1 integrin heterodimer emerged as one of the most relevant biological predictors 
of OS along with 17p deletion [102]. Other well-established prognosticators, such as 11q 
deletion, CD38 expression and ZAP70 expression, turned out to be endowed by much 
lower prognostic power when either 17p deletion, IGHV mutational status or CD49d 
expression was concurrently available [102]. A possible explanation might be that there 
appears to be alterations in the NFκB signaling depending on differences in sensitivity to 
microrenvironmental stimuli between CD49d+ and CD49d- CLL [46]. 
CD38 is expressed on cells of hematopoietic origin and can act as a receptor or as an 
enzyme regulating the intracellular calcium level. CD38 is highly expressed in activated B 
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and T cells as well as NK cells and dendritic cells and a high expression is associated with 
unmutated IGHV status, a poorer response to chemotherapy and a shorter OS [26, 145]. 
However, CD38 is difficult to use in clinical practice as the expression may vary during the 
course of the disease, its expression in CLL cells within a blood sample is heterogenic and 
a defined cut-off value for positivity is lacking  [145]. 
ZAP70 is a tyrosine kinase associated with high responsiveness to BCR stimulation in 
CLL cells and enhances migration toward chemokines and response to survival stimuli 
from the microenvironment. Normal, as well as malignant B cells express ZAP70 at 
various differentiation stages. High ZAP70 expression has been associated with disease 
progression and short OS [144]. Since ZAP70 is an intracellular protein, detection with flow 
cytometry is complicated and mRNA measurement might be more reliable [77]. IGHV 
unmutated cases express higher levels of ZAP70 and CD38 compared to the mutated [144]. 
Expression of lipoproteinlipase (LPL), an enzyme suggested to play a role in cell 
adhesion, correlates to poor prognosis and is associated with poor-prognostic markers. LPL 
also seems to be able to distinguish patients with otherwise good prognostic markers and 
might be valuable in the prognostic evaluation in low-risk patients at diagnosis [77]. 
CLLU1 (CLL upregulated gene 1) is a gene uniquely expressed in CLL cells. High 
expression is associated with advanced disease, other poor-prognostic markers and a 
shorter time to treatment. However, it is neither an independent marker for OS nor a 
predictive marker. CLLU1 may have a role as a prognostic marker in younger patients with 
favourable prognostic markers to identify who are likely to require treatment [77]. 
Several studies have revealed differences in miRNA expression between prognostic 
subgroups. Even though results have been discordant due to methodological differences 
and variations in patient material some miRNA may be used as prognostic markers [77]. 
Due to the limited information on the independent prognostic value, it is difficult to 
know how to interpret the different prognostic markers described above. Efforts are made 
to combine the “best” markers in a “CLL prognostic index”. A recent model [140] based on a 
full array of genetic characteristics defined 4 hierarchically classified subgroups based on 
mutations of TP53, BIRC3, NOTCH1 and SF3B1 in addition to the established genomic 
aberrations [76]. However the model did not reach the C-statistic threshold (c > 0.70) 
necessary to have utility in the individual patient [150] and was not confirmed by others [86, 93]. 
Another attempt to develop a comprehensive prognostic index evaluated 23 clinical 
biological and genetic markers [138]. Their index (c=0.75) classifies patients into four risk 
groups based on 8 independent risk factors (deletion 17p, thymidine kinase,  
β2-microglobulin, unmutated IGHV, ECOG > 0, deletion 11q, male sex and age > 60 
years). To be classified as very high risk, deletion of 17p was required. In this index, serum 
thymidine kinase and β2-microglobulin were considered as the second most important risk 
factors. However, the roles of novel mutations such as NOTCH1, SF3B1 and BIRC3 as 
well as CD49d expression need to be re-evaluated in the context of this model. 
In addition to the difficulties in interpreting prognostic markers, knowledge about 
predictive relevance for the novel biomarkers transferrable to clinical practice is still very 
limited and there is an immediate need to identify biomarkers which can predict therapy 
response.
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2 TREATMENT OF CLL 
The most important patient subgroups in clinical practice and treatment decision making 
are the few patients in the very-high-risk group (4%) with a dismal 5-year survival of 19% 
and those in the low-risk group (25%) with a 95% 5-year survival and a median time to 
first therapy of > 10 years [151]. 
2.1 Treatment indications 
There is no curative treatment for CLL with the exception of the very few patients who 
undergo allogeneic stem cell transplantation. Patients without symptoms shall be subject to 
“wait and watch” and where neither bone marrow biopsies nor CT scans are recommended. 
The use of prognostic markers is not recommended in this situation since these might turn 
the” watch and wait” into a “watch and worry” situation. 
However treatment should be applied if the disease is active i.e. in the presence of 
cytopenias due to bone marrow failure, or if rapidly progressing lymphadenopathy or bulky 
lymph nodes (> 10cm), or if a rapid doubling of the lymphocyte counts (≤ 6months) or if 
severe constitutional symptoms (fever, night sweats, weight loss, fatigue) occur [4, 113]. It 
should be emphasized that the absolute lymphocyte count is not a criterion for initiation of 
treatment and that severe constitutional symptoms as the only criterion to start therapy are 
rare [152]. 
2.2 First line treatment 
Before treatment initiation, a bone marrow biopsy and an evaluation of 17p deletion/TP53 
mutation is recommended. The latter is to be done due to the strong correlation with 
chemorefractoriness and early relapse [84, 113]. Biological prognostic markers such as 
mutational status, CD38, ZAP70 and CD49d are currently considered insufficient to 
precisely determine the clinical fate of individual patients and should not be used to make 
treatment decisions in CLL patients. The value of the new prognostic markers (NOTCH1, 
SF3B1, BIRC3) needs to be confirmed by prospective studies and reliable and reproducible 
detection methods need to be established before they can be used in clinical routine [152]. 
The treatment strategies shall be highly individualized and the clinical stage and 
genetic risk of the disease as well as the patient’s fitness and the treatment situation (first- 
vs. second line; response vs. non-response to last treatment) shall be considered when 
selecting a treatment for CLL [137]. The patient’s fitness will be influenced by age, organ 
function and comorbidities. Since CLL most often affects elderly people, individual 
expectations and quality of life should be considered when choosing treatments. 
2.2.1 Good physical condition 
Chemoimmunotherapy is established as the gold standard for first-line treatment of fit 
patients without 17p deletion or TP53 mutation. A combination of fludarabine, 
cyclophosphamide and rituximab (FCR) has shown overall response rates (ORR) of about 
90% and complete remission (CR) rates of 44% and has prolonged PFS (57.9 months) and 
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improved OS [81, 153]. FCR is a standard treatment in most patients younger than 65 years of 
whom some, especially those with mutated IGHV genes or with trisomy 12, may have very 
long remissions. Even though FCR has improved response rates and survival it is less well 
tolerated in patients > 70 years of age where severe neutropenia tend to be more frequent 
and patients remain susceptible to infections up to two years after discontinuation of 
therapy by exacerbating the immunodeficiency already present in CLL [152]. Therefore FCR 
is not a first-line treatment for all and it is generally too toxic in frail, elderly patients who 
constitute the majority of patients in the clinic. 
For those with borderline fitness status a combination of bendamustine (90mg/m2 on 
Days 1 and 2) with rituximab (BR) is an option. Bendamustine differs structurally from 
other alkylators by its benzimidazole ring. Like several other alkylating agents, 
bendamustine crosslinks DNA and causes cytotoxic single- as well as double-strand breaks. 
However bendamustine appears to cause more extensive and more long-lasting DNA 
strand breaks which may result from its different structure [154]. BR has been shown to 
achieve similar response rates (ORR 88%, CR 23.1%) but induces less neutropenia (19.7% 
vs 34%) and severe infections (7.7% vs 25%) than FCR [155]. 
Recent phase III data shows that FCR appears more efficient than BR as first-line 
treatment of fit patients as it shows a higher rate of CRs (47.4% vs. 38.1%) as well as 
longer PFS in patients < 65 years (not reached vs. 36.5 months). However these advantages 
might be balanced by a higher rate of toxicity, in particular neutropenia and infections, 
associated with FCR and the superior PFS for FCR disappeared in the elderly  [156]. 
In the light of the new results, where the associated toxicities with FCR may 
sometimes overcome the benefits in the individual patient, no firm recommendation of one 
regimen over the other can be given at the present time regarding the first-line use in CLL 
patients with good physical fitness. 
2.2.2 Impaired physical condition 
Patients with an impaired physical condition, who are considered inappropriate for FCR or 
BR may be offered a mild regimen such as chlorambucil for symptom control. 
Chlorambucil is an orally available alkylating agent with low toxicity and cost but also with 
low response rates when used as monotherapy (ORR up 30-72% and CR 0-7%) and a 
median PFS of 8-18 months [157-159]. Bendamustine alone shows improved responses but 
greater toxicity and no survival benefit compared to chlorambucil alone and is therefore not 
recommended alone in first line treatment for frail patients [152, 159]. Until recently no 
treatment had proved to be superior to chlorambucil in this patient population [160]. 
Therefore more effective but tolerable treatment choices are needed. Recent data suggests a 
combination of chlorambucil and a CD20 antibody might be such an option [161, 162]. 
The chimeric type 1, CD20 antibody rituximab is widely utilized as first-line therapy in 
unfit patients due to its limited toxicity but there is no such indication in Europe. If used at 
standard doses, rituximab as a single agent is much less efficient in CLL than in follicular 
lymphoma, with a response rate of only 13% [163]. This might be due to the dim expression 
of CD20 on CLL cells [152]. Phase II studies combining rituximab with chlorambucil in 
elderly patients with comorbidities showed superior ORR (84% and 82.4% ) as well as CR 
rates (10% and 16.5%) and PFS (23.5 and 34.7 months) than was previously achieved with 
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chlorambucil alone [157, 164]. Median OS was not reached with a median follow up of 30 and 
34 months respectively. The combination was well tolerated in both studies with toxicities 
comparable to chlorambucil monotherapy. 
Another CD20 antibody is ofatumumab, a fully human type 1 monoclonal antibody 
(mAb). It targets a unique epitope of CD20 with a higher binding affinity in comparison 
with rituximab. This results in a stronger complement-dependent cytotoxicity but similar 
ADCC and apoptosis induction and a slow release from the target compared to rituximab  
[165]. Ofatumumab is licensed by FDA (Food and Drug Administration) and EMA European 
Medical Agency) as monotherapy in double refractory ((DR) i.e. refractory to both 
fludarabine and alemtuzumab) (see 2.4.3) CLL. A phase III trial in the first-line setting with 
unfit patients, considered inappropriate for fludarabine-based treatment, showed that the 
addition of ofatumumab to chlorambucil is more efficacious without an increase of severe 
side effects ( ORR 82% vs 69%, CR 12% vs 1% and PFS 22.4 vs 13.1 months) [162]. Of 
note, mutated NOTCH1 might be a predictive marker for reduced benefit from the addition 
of ofatumumab to chlorambucil [142]. In contrast patients with SF3B1 mutation appeared to 
benefit from ofatumumab addition [166]. In 2014 the combination of ofatumumab and 
chlorambucil was approved by FDA and EMA for the treatment of previously untreated 
CLL patients, for whom fludarabine-based therapy is considered inappropriate. 
A third combination with chlorambucil in unfit patients is the one with obinutuzumab 
(GA101). Obinutuzumab is a humanized glycoengineered type 2 CD20 antibody, In 
preclinical studies it binds CD20 with a higher affinity and has increased ADCC activity 
and direct cell killing but has lower CDC than type I CD20 antibodies [167]. A phase III trial 
in untreated CLL patients with comorbidities investigated the addition of obinutuzumab to 
chlorambucil treatment compared with rituximab-chlorambucil and chlorambucil 
monotherapy. Patients receiving obinutuzumab-chlorambucil had a significantly better 
quality of response with higher CR rates (20.7% vs 7.0%), were more frequently minimal 
residual disease (MRD) negative (19.5% vs 2.6%) and had prolonged PFS (median PFS 
27.6 vs 16.3 months) compared to those treated with rituximab-chlorambucil [161]. Benefit 
with regard to OS was seen but did not reach significance and the benefit from 
obinutuzumab was evident in all analyzed subgroups with the exception of those with 17p 
deletion. Adverse events (AE) were more common in the antibody groups and were most 
frequent with obinutuzumab where more infusion-related reactions were seen (20% vs 4%) 
but the rates of serious infections (11-14%) did not differ between the groups. Notably 
there were 14 cases of tumor lysis syndrome (TLS) in the obinutuzumab-chlorambucil 
group versus zero in the other groups. Obinutuzumab appears to be more potent and 
equally well tolerated as rituximab in combination with chlorambucil in unfit patients 
which led to FDA approval for this combination for untreated patients not eligible for more 
intensive therapy. 
The patients in the studies evaluating chlorambucil in combination with either 
ofatumumab or obinutuzumab are not strictly comparable and a head-to-head comparison 
of both antibodies is warranted. 
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2.2.3 17p deletion or TP53 mutation  
Patients with 17p deletion or TP53 mutation carry a very dismal prognosis. This group 
represents only about 5% at diagnosis but the group increases sharply up to 40-50% in the 
refractory situation [76, 80]. There is a small subgroup of patients with TP53 disruptions who 
may have a benign clinical course over a prolonged time period [168, 169]. However the ORR 
is unsatisfactory and CRs are rare for the vast majority when treated with chemotherapy 
e.g. FCR or BR [81, 155]. Even if they respond, patients will usually relapse within a short 
time and when they do the median life expectancy is short [170]. There are limited data on 
the most efficacious first-line treatment for CLL patients with 17p deletion/TP53 mutations 
since most trials include few patients with these abnormalities and randomized controlled 
trials have not been performed specifically for this subgroup. Current treatment approaches 
rely on agents able to induce apoptosis in a TP53 independent fashion. 
Alemtuzumab, an anti-CD52 mAb (section 2.4.2) has been used as single agent in the 
first-line setting with an ORR of approximately 80% [158, 171]. Alemtuzumab is effective in 
patients with 17p deletion with no significant differences in response rates between patients 
with TP53 abnormalities and those without  [172] and neither 17p deletion nor TP53 
mutation had an impact on PFS or OS [172-174]. This suggests efficacy independent of the 
p53 signaling pathway and therefore alemtuzumab plays an important role in the treatment 
of these patients and can be considered upfront for patients with 17p deletion or TP53 
mutation [4]. 
However, given the improved toxicity profile of ibrutinib (see 3.2.1) over 
alemtuzumab, ibrutinib may represent the best available option for these patients [175] 
Emerging drugs, such as the BCL-2 inhibitor ABT-199 (GDC-0199) also provide hope for 
such patients (see 3.2.3). 
In summary, there is currently no gold standard for the treatment of patients with 17p 
deletion or TP53 mutation. In the absence of comparative trial data there are no firm 
recommendations but in clinical practice agents such as ibrutinib and alemtuzumab are 
usually the treatment of choice and allogeneic stem cell transplantation is often considered 
early. These patients still remain a challenge and should ideally be treated within clinical 
trials exploring new therapeutic agents. How to treat patients with subclonal TP53 defects 
are not yet stated but since their prognosis is similar to those with clonal defects [22] it might 
be proper to manage them in the same way. 
2.3 Treatment evaluation and minimal residual disease (MRD) 
Definitions of response are stated in IWCLL guidelines [113]. Neither CT scans nor bone 
marrow or MRD evaluation are mandatory yet strongly recommended in clinical trials [113]. 
The high CR rate with FCR raised the question of the value of achieving MRD 
negative status as a treatment end-point. Methods to study MRD in CLL include allele-
specific oligonucleotide polymerase chain reaction (PCR) for the clonal IGHV gene and 
multicolor flow cytometry which can reach the 0.01% sensitivity recommended in IWCLL 
guidelines [113]. The use of NGS techniques might become an additional way of detecting 
MRD in the future [176]. MRD status from blood and bone marrow may be discordant where 
blood might be a less sensitive, especially during and for several months after treatment 
with monoclonal antibodies. This might be due to the importance of the microenvironment 
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in CLL cell growth and survival. Therefore bone marrow is the site recommended for MRD 
evaluation in the absence of definitive data, but remains an issue for study [177, 178]. 
Low level of MRD in bone marrow or peripheral blood appeared to be associated with 
improved OS irrespective of the treatment of choice [179]. Further studies also showed that 
MRD negative status in blood or bone marrow was independently associated with longer 
PFS and OS after first-line treatment with FCR  [180, 181]. It has even been suggested that 
early MRD eradication may prompt treatment discontinuation since there was no 
significant difference in PFS among patients achieving MRD negativity regardless of the 
number of courses, and patients who were MRD negative and continued treatment did not 
seem to improve PFS [180]. Such a strategy might reduce associated complications such as 
infections, important in elderly, and second malignancies, important in young patients. The 
level of MRD also appears to be associated with PFS where the higher MRD level the 
shorter PFS  [181]. Mutated IGHV status and trisomy 12 were independently associated 
MRD negativity where the latter might be explained by a higher level of CD20 expression 
associated with trisomy 12 maybe favoring a greater sensitivity to rituximab [180]. MRD 
negativity appears to be of prognostic significance in patients with TP53 abnormalities as 
well [181, 182]. However, patients with TP53 mutations have a relatively short PFS even if 
MRD negative [80] which suggests that both TP53 abnormalities and MRD response 
independently predict for PFS. 
2.4 Treatment of relapsed/refractory CLL 
Relapse and disease progression in patients treated with chemotherapy may occur because 
of clonal evolution of CLL cells. In the relapsed situation, mutations affecting p53 function 
are more frequent resulting in chemoresistant disease [1, 84]. However, TP53 abnormalities 
only explain a fraction of these cases. The approach to relapsed CLL is similar to the one 
before first-line therapy and treatment initiation should not occur until patients are 
symptomatic and bone marrow and cytogenetics should be analyzed [113]. However, apart 
from the recommendation to repeat the first-line therapy in the case of a relapse > 24 
months after initial treatment provided by the European Society of Medical Oncology 
(ESMO) [183] little is known about which therapies to use in the case of an earlier relapse. 
Progression within 24 months after chemoimmunotherapy is regarded as unsatisfactory 
[178] and is associated with a low proportion of responses and short survival times when 
chemoimmunotherapy is used [170, 184]. Failure to achieve at least a partial remission (PR) or 
a relapse within 6 months after last treatment is the current definition of refractoriness in 
CLL [113]. Approximately 80% of fludarabine refractory patients harbor multiple molecular 
alterations of which TP53 is the most common. The lesions are to some extent are mutually 
exclusive [94]. Patients refractory to fludarabine have a poor prognosis and usually show 
limited response to salvage chemotherapy with response rates ranging between 22% and 
34% and even those who respond usually experience a very short remission duration with a 
median OS ranging between 9 and 19 months [172, 185, 186]. These subgroups, patients being 
refractory to fludarabine or experiencing a short remission after intense therapy (e.g. FCR), 
are considered “ultra-high-risk” together with the ones harboring TP53 abnormalities [170]. 
High-risk CLL is defined by 11q deletion, unmutated IGHV gene or advanced stage. 
30 Treatment of CLL 
 
It is difficult to compare safety and efficacy of different regimens in relapsed or 
refractory CLL. Characteristics of patients enrolled in studies differ widely and second-line 
therapies after first-line FCR appears very heterogeneous [153]. Specific treatment 
recommendations for relapsed patients are therefore lacking. However, the ORR after 
second-line therapy will depend on the length of initial remission which should influence 
the choice of relapse treatment and consolidation approaches. 
The treatment options for ultra-high-risk CLL are limited as well and 
recommendations are not based on comparative trial data. Allogeneic stem cell transplant 
shall be considered and participation in clinical trials testing novel agents is particularly 
recommended. 
2.4.1 Chemoimmunotherapy 
FCR appears more efficacious than FC in the relapsed/refractory setting [187] and has been 
extensively tested. The ORR is about 70% with 25-30% CR and a PFS of approximately 
20-30 months. However, the outcome is affected by the type of previous treatment [184] with 
a poorer outcome for those refractory to fludarabine [185, 188]. 
A study investigating FCR as salvage therapy showed an ORR of 73% with 25% CR 
whereas in the subgroup of fludarabine refractory patients the ORR was 58% with CR rate 
of 6% [188]. Another study only including fludarabine-sensitive patients at relapse after first 
line treatment also achieved higher response rates (ORR 69.9% CR 24.3%) [187]. The poorer 
outcome of those refractory to fludarabine might be due to enriched TP53 abnormalities in 
this subgroup. Results for FCR in patients with 17p deletion are no good. Response rates 
are markedly poor with almost no complete remissions and short PFS and OS of less than 
one year [184, 187, 188]. The most common toxicity of FCR is myelosuppression where about 
two thirds of the patients experience ≥ grade III neutropenia [184, 188] and approximately 16% 
experience ≥ grade III infections [184, 187, 188]. Many patients, sometimes the majority and 
especially those > 70 years of age, are not able to receive 6 courses of FCR due to toxicity 
[184, 187, 188]. FCR combined with bevacizumab, a humanized mAb targeting VEGF (vascular 
endothelial growth factor), was recently investigated. [189]. The results showed no benefit on 
PFS or OS of the addition of bevacizumab and patients with 17p deletion displayed a 
poorer outcome. Notably, the proportions of high-risk features such as 17p deletion were 
significantly higher in the FCR-bevacizumab group compared to the FCR group. 
Bendamustine is only partially cross-resistant with other alkylating agents and 
fludarabine and is less toxic than FCR. When used as monotherapy in the 
relapsed/refractory setting in doses ranging from 70mg/m2 to 100mg/m2 (day 1 and 2) the 
ORR was about 50% with some CRs [190]. However no patients with 17p deletion were 
investigated in this trial. BR as salvage therapy achieved ORR and CR rates of 59% and 
9% respectively in a higher risk population and the durations of remissions were about  
1 year [191]. There are subgroups that seem to benefit much from BR. Most patients with 11q 
deletion or trisomy 12 responded (ORR 92.3% and 100%) as well as those sensitive to 
fludarabine (ORR 60.5%) whereas those with 17p deletion or refractory to fludarabine 
displayed poorer responses (ORR 7.1% and 45.5%). When comparing BR to FCR in the 
relapsed/refractory setting the adverse effects of BR compare favorably (neutropenia  
≥ grade III 21.3% vs 42-62%). 
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Bendamustine in combination with ofatumumab has been investigated in 
relapsed/refractory patients as well. Recent data from a phase II multicenter trial [192] 
compared favorably to BR showing an ORR of 72.3% with 17% CR [191]. However TP53 
disruptions, present in 22% of the study population, were significantly associated with 
lower response rates (ORR 30%) as well as shorter PFS. Bulky lymphadenopathy was also 
associated with lower response rates. Myelosuppression was the most common toxicity 
with ≥ grade III neutropenia developed in 61.7% i.e. higher than observed with BR [191] but 
similar to that reported with FCR [188] (23% and 66% respectively). Despite the significant 
proportion of neutropenia, infections ≥ grade III were only recorded in 6% which is 
comparably low to BR and FCR (12.8 and 16% respectively. There was no difference in 
response rate or toxicity with respect to age. 
2.4.2 Alemtuzumab 
Alemtuzumab is a recombinant, humanized mAb. It is directed against CD52, a 
glycoprotein of unknown function, expressed at high density on most normal as well as 
malignant B- and T-lymphocytes but not on hematopoietic stem cells [193]. Binding of 
alemtuzumab to CD52 is considered to cause cell death by ADCC, CDC and possibly also 
by direct cytotoxicity [194]. New preclinical data suggest that antibody-mediated macrophage 
phagocytosis might be a major mechanism of alemtuzumab-dependent cellular cytotoxicity 
[195]. Alemtuzumab is mainly used as treatment for relapsed or refractory CLL with an 
overall response rate of about 33%, a response duration of around 9 months [194, 196] and an 
OS of approximately 19 months [197] when used as monotherapy. 
Alemtuzumab shows profound activity in clearing blood and bone marrow disease but 
its effectiveness in bulky (> 5cm) lymph nodes is limited [171, 194, 196, 198]. An option to 
overcome this shortcoming may be the addition of corticosteroids which induce apoptosis 
in a p53-independent way. Alemtuzumab in combination with methylprednisolone 
(CamPred) achieved an ORR of 88% with 36% CRs in patients with 17p deletion/TP53 
mutation [182]. In this study neither lymphadenopathy nor age had any significant influence 
on response or survival even though the infection rates among the older patients were 
higher. However, the duration of response was short with a median PFS and OS of 11.8 and 
23.5 months respectively. Combining alemtuzumab with dexamethasone (CamDex) also 
appeared feasible with high response rates (ORR 79% CR 4%). However, PFS and OS 
were short (10.3 and 21.3 months respectively) with this combination as well [199].  
Full dose alemtuzumab combined with FC or FCR appears to improve response rates 
but is accompanied with considerable toxicity. Neither the addition of cyclophosphamide to 
CamPred nor alemtuzumab combined with FCR or mitoxantrone were feasible due to 
higher toxicity and excess mortality due in particular to infections [152]. 
However a lower dose of alemtuzumab might be feasible in combination with 
chemotherapy. Low-dose alemtuzumab in combination with FC (FCA) in the first-line 
setting showed an increased PFS in patients younger than 65 years compared to FC [200]. 
Unfortunately there was no benefit of FC in the subgroup with 17p deletion. A recent trial 
combining low dose of alemtuzumab (30mg in 3 days every third week) with gemcitabine 
in relapsed/refractory high-risk CLL patients [201] had no safety problems. This study 
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showed an ORR of 65% including 29.6% CR with a median PFS and OS of 15.4 and 24 
months respectively. Bulky disease was associated with a shorter OS. 
Another option is to combine alemtuzumab with bendamustine. Phase I/II data on this 
combination in relapsed/refractory CLL showed an acceptable safety profile with an ORR 
of 68% including 24% CR and a median PFS of 17.3 months. Responses were consistent 
(57%) in patients with TP53 disruptions but the response duration was shorter [202].  
The major side effect of alemtuzumab is a profound, long lasting T- and NK-cell 
depletion leading to an increased risk of infection, in particular reactivation of CMV [203, 
204]. Prophylaxis with valaciklovir and cotrimoxazole, or equivalent, is therefore mandatory 
and monitoring for CMV should be done liberally [4]. About 35-40% of patients experience 
≥ grade III infections despite prophylaxis [172, 198]. Infusion-related symptoms have been 
overcome by a switch to subcutaneous administration without a loss of efficacy [171, 172]. 
In summary alemtuzumab-based regimens can yield a substantial proportion of CRs in 
high-risk patients, although of short duration. Combining alemtuzumab with bendamustine 
appears as effective as a combination with FC but safer. It might be an option in patients 
who have previously received FCR, particularly if pancytopenia is present due to a heavily 
infiltrated bone marrow, or as a bridge to transplant in patients with TP53 disruptions. 
Alemtuzumab for the treatment of CLL was withdrawn from the market in Europe and the 
US but is still available through a free, named-patient program. 
2.4.3 Ofatumumab 
In the initial phase II study conducted in patients with relapsed/refractory CLL the response 
rate was 50% but the median time to disease progression was only 3.5 months [205]. A phase 
II multicenter study was then conducted in patients who were refractory DR or had bulky 
disease refractory to fludarabine (BFR). Ofatumumab was well tolerated by the majority of 
the patients. The most common AEs were infusion–related reactions which predominantly 
occurred during the first and second infusions. Response rates were 47-58% but the 
remission duration of all patients was short and the majority relapsed while being on 
therapy (median PFS 5.9 -5.7 months respectively) [206]. Even though patients with 17p 
deletion responded, the results in this subgroup as well in those with bulky disease were 
poorer. However, the results from this trial promoted the initial registration of ofatumumab 
as single agent for these patient groups in Europe and the US. Ofatumumab monotherapy is 
also effective and well-tolerated in patients previously treated with rituximab [207]. A recent 
retrospective follow-up of ofatumumab in the relapsed/refractory clinical setting showed an 
ORR of 23% and a median PFS and OS of 5 and 12 months respectively. The safety profile 
was consistent with that observed in clinical trials [208]. 
2.4.4 Allogeneic stem cell transplantation 
Allogeneic stem cell transplantation (ASCT) is still the only curative treatment option in 
CLL with an OS of 30-70% [209]. ASCT is recommended if evidence of TP53 abnormalities, 
no response or relapse within 12 months after purine analogues or relapse within 24 months 
after purine analogue based combinations, by the European Group for Blood and Marrow 
Transplantation (EBMT) [209]. The crucial component of ASCT is the graft-versus-leukemia 
(GVL) effect in which donor hematopoietic cells mount an immune response against the 
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malignant clone. The mechanistic basis of GVL is complex but is known to be primarily  
T cell mediated [210]. The importance of GVL is supported by several findings. First is the 
phenomenon that relapse incidence seems to decrease with time showing a plateau in 
disease-free survival. Second there is a difference in long-term molecular responses 
between allogeneic and autologous transplantation. Third, myeloablative therapy alone is 
generally not sufficient to cure CLL and reduced-intensity conditioning (RIC) may provide 
the same cure rate. Finally there are reports on the efficacy of donor lymphocyte infusion 
[209, 211]. Myeloablative treatment is generally not tolerated in elderly and comorbid 
individuals. However, even though no randomized trial comparing RIC with myeloablative 
conditioning is published, RIC appears sufficient as conditioning before ASCT and has 
expanded the eligible population including patients older than 70 years [209, 212]. Even with 
RIC, ASCT is associated with relevant non-relapse mortality (NRM). Grade III-IV 
infections occur in up to 60% even though only a few are life threatening. NRM mounts up 
to 15% to 25% during the first two years after transplantation largely due to complications 
of acute and chronic graft versus host disease (GVHD) which affects up to 20%. Due to the 
high NRM, ASCT is only recommended for those with a good performance status [209]. 
A challenge treating TP53 disrupted patients is that the response achieved prior to 
transplantation appears to be an important factor influencing long term success [209, 213]. 
Consolidation with ASCT has shown ability to overcome the impact of 17p deletion and 
long term remissions have been documented for these patients (OS 57% at 5 years and 59% 
at 4 years) [212, 213]. Neither TP53 nor SF3B1 nor NOTCH1 mutations appear to have an 
impact on long term disease control [209]. Retrospective data showed higher relapse rates 
after in-vivo T cell depletion of the graft with alemtuzumab during conditioning for ASCT 
[214] and for this reason a 3 months wash-out phase after alemtuzumab may be considered. 
In conclusion, consolidation with ASCT is a treatment option to strongly consider in 
patients with TP53 abnormalities. There is no consensus regarding conditioning before 
ASCT due to lack of data but the outcome is better in absence of bulky lymphadenopathy 
and if the patient is in remission at the time of transplant [212, 213]. 
 
In summary, fit patients who are not refractory to fludarabine and without TP53 
abnormalities may benefit from FCR as salvage therapy especially if they are not too 
heavily pretreated [184, 187, 188]. Due to the favorable toxicity profile BR might be a preferable 
salvage option in the elderly without TP53 disruptions especially for patients with trisomy 
12. Phase II study results suggest that bendamustine in combination with ofatumumab 
might be a good option in frail patients. For patients harboring TP53 disruptions, 
alemtuzumab as single agent or in combination with high-dose steroids (if bulky disease) is 
an option as well as ofatumumab. Outside clinical trials alemtuzumab in combination with 
high-dose steroids and ASCT as consolidation, due to the otherwise short duration of 
remission, is an option to consider for fit patients harboring TP53 abnormalities [215, 216]. 
Combination therapy with alemtuzumab or ofatumumab is to be investigated further. 
However, on the basis of recent results ibrutinib (see 3.2.1) might be the best salvage 
therapy for relapsed CLL irrespective of genomic risk. 
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3 NEW AND EMERGING THERAPIES 
 
 
 
Figure 4. CLL pathogenic mechanisms and examples of targeted treatment options. 
a) The BCR with downstream signaling of SYK, LYN and BTK are targets for small molecules. b) Multiple 
epitopes on the CLL cell are targets for antibody-based therapies. c) The function of at least one of the genes 
deleted in 13q deletion is down-regulation of the anti-apoptotic gene BCL-2 and the deletion harbors miRNAs 
that are negative regulators of BCL-2. Epigenetic changes might play a role in regulation of miRNA 
transcription. Small molecule BH3 mimetics or HDAC inhibitors can target these changes.  
d) Stromal and T cell interactions contribute to CLL pathogenesis. Lenalidomide was shown to target the 
interaction with T cells. Chimeric antigen receptor T cells or allogeneic T cells may provide an effective 
immune response to CLL cells. The crosstalk between CLL cells and accessory cells up-regulates anti-
apoptotic proteins, such as survivin and BCL-2 which may be targeted by small molecules. 
Ag, antigen; CDK, cyclin-dependent kinase; HDAC, histone deacetylase; Me, methyl group; NFAT, nuclear 
factor of activated T cells; PLC-γ, phospholipase C-γ; SDF1, stromal cell-derived factor 1;VEGFA, vascular 
endothelial growth factor A. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer 10, 37-50 (January 2010), Zenz T et al. 
Copyright 2010. 
3.1 Novel antibodies 
Monoclonal antibodies are approved for use in CLL in the first line mainly in combination 
with chemotherapy (rituximab, ofatumumab, obinutuzumab) as well as single-agent 
therapy in the refractory setting (alemtuzumab (until recently), ofatumumab). In addition a 
new generation of anti-CD20 antibodies has recently become available for preclinical and 
clinical studies and antibodies directed against new targets are currently investigated 
(Figure 4b). 
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Anti-CD20 
Type I and II mAbs differ in their CD20 binding and activation of cell death pathways. 
Type I CD20 antibodies are associated with a stronger CDC but only low levels of direct 
cell death. The occurrence of resistance to type I mAbs seems to be associated with the loss 
of CD20 by “shaving” or antibody internalization. Type II CD20 antibodies have a lower 
CDC effect but can induce increased direct cell death. Less resistance to therapy can be 
expected due to less antigenic internalization which may prolong the presence of the 
antibody on the cell surface which likely increases ADCC [167]. 
Rituximab is a type I chimeric anti-CD20 antibody which exerts its function via CDC 
and ADCC [217]. 
Obinutuzumab represents the first humanized glycoengineered type II mAb. Preclinical 
studies showed a superior killing activity and a greater B-cell depletion than rituximab [167]. 
A recent phase I/II trial of obinutuzumab monotherapy in relapsed or refractory CLL 
investigated the safety at different doses in phase I and efficacy at an established dose 
(1000mg) in phase II. The overall end-of-treatment response was 62% (all partial) the 
median PFS was 10.7months [218]. The toxicity profile was acceptable (transient 
neutropenia, thrombocytopenia) with a dose dependent incidence of AEs. Nearly all 
patients experienced infusion reactions. As significantly elevated cytokine levels were 
observed together with a rapid and profound B-cell depletion, cytokine release from 
malignant cells might be the reason for the high frequency and intensity of infusion related 
reactions (IRR). However, lymphocyte counts and lymphadenopathy were no strong 
predictors of IRR In the absence of validated risk factors, all patients have to be closely 
monitored during the first infusion. Cases of TLS have been observed as well [218]. In 
summary obinutuzumab monotherapy appears active in advanced CLL but shows a higher 
toxicity than rituximab. 
Tumor burden appears to contribute to the clearance of obinutuzumab in the way that 
those patients with a higher tumor burden have a faster clearance of obinutuzumab [218]. The 
optimal dose, schedule of administration and duration of treatment is still elusive and 
further studies are warranted. An ongoing study in the first-line setting compares single 
agent obinutuzumab at doses 1000 or 2000mg in untreated CLL patients (NCT 01414205). 
Given the encouraging results with obinutuzumab combined with chlorambucil first-
line [161] other combinations are investigated. A non-randomized study in previously 
untreated patients investigates obinutuzumab in combination with either FC or 
bendamustine. Preliminary results show ORR and CR of 90% and 20% respectively in the 
FC arm and 62% and 10% respectively in the bendamustine arm [219]. Approximately 90% 
in each arm experienced IRR but the combinations were rather well tolerated otherwise. At 
a median follow-up of about 1 year none of the patients had experienced disease 
progression. Ongoing studies investigate obinutuzumab in combination with otlertuzumab, 
PI3Kδ inhibitors or ABT-199(GDC-0199) [167].  
There are several anti-CD20 mAbs under development. 
Ocaratuzumab is a humanized anti-CD20 type I antibody designed for effective ADCC 
at very low concentrations. Preclinical results showed more ADCC compared to rituximab 
or ofatumumab and at low concentrations similar ADCC to obinutuzumab. The possible 
lower doses might facilitate future sub-cutaneous administration, potentially reducing the 
costs and at the same time being more convenient to patients [217]. 
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Ocrelizumab is a humanized anti-CD20 type I antibody which binds to a different 
CD20 epitope than rituximab with improved ADCC and reduced CDC and improved  
Fcγ-binding. Clinical responses have been achieved in follicular lymphoma but no clinical 
results from CLL are available [217]. 
Veltuzumab is also a humanized anti-CD20 type I antibody which binds to a different 
CD20 epitope than rituximab with improved ADCC and reduced CDC and improved  
Fcγ-binding. Early studies in non-Hodgkin lymphoma (NHL), including CLL have shown 
responses and further clinical trials in NHL are ongoing [217]. 
Ublituximab (TG-1101) is a chimeric anti-CD20 type I antibody with improved  
Fcγ-binding which induced higher ADCC activity against CLL cells compared to rituximab 
at lower concentrations. However, the ADCC was lower in CLL cells from patients with 
17p deletion [220]. Ublituximab has shown promising results in a first-in-human phase I/II 
clinical trial with 45% ORR in advanced CLL at a relatively low dose [221]. A phase I/II 
study of ublituximab monotherapy in relapsed/refractory B cell lymphoma (including CLL) 
showed an ORR of 67% in CLL and no dose-limiting toxicity (DLT)  [222]. 
 
Anti-CD37 
CD37 is a transmembrane protein expressed on normal mature B cells. It is upregulated in 
CLL cells but is expressed at very low density on monocytes, macrophages, neutrophils,  
T cells, plasma cells and dendritic cells. 
Otlertuzumab (TRU-016) is a CD37-specific protein consisting of antibody-derived 
single chain variable fragments linked to Ig constant domains. It is similar to an antibody in 
its functionality and pharmacokinetic properties but is smaller and shows superior NK cell 
mediated ADCC compared to rituximab [217]. A phase I study evaluating safety in CLL 
patients did not identify any maximum-tolerated dose (MTD). The most frequent AEs 
(IRR, fatigue, nausea and diarrhea) were not dose related [223]. However, as a single agent it 
appears to have modest clinical activity in CLL (PR 23% CR 0%) and lower response rates 
in 17p deleted patients (16%) [223]. Responses were more common in untreated or less 
treated patients. Preclinical data indicated additive or synergistic activity with rituximab 
and bendamustine [224]. The combination otlertuzumab and bendamustine compared to 
bendamustine alone was investigated in relapsed CLL [225] and appeared tolerable with an 
ORR of 80% (20% CR) compared to 42% (4% CR) for bendamustine alone. However no 
patients with 17p deletion responded. In addition, whether otlertuzumab combined with 
bendamustine is better than BR remains unknown. Otlertuzumab combined with rituximab 
is investigated in previously untreated CLL and seems feasible but to date there are no data 
on response rates [226]. 
 
Anti-CD23 
CD23 is expressed on B cells and on most CLL cells. It is a B-cell activation marker and 
CLL cells typically overexpress CD23 compared to normal B cells [217]. Lumiliximab is a 
chimeric anti-CD23 antibody which mediates cell death through ADCC and CDC. 
Preclinical studies showed antitumor activity against CLL cells. However, a phase III trial 
comparing FCR combined with lumiliximab to FCR closed prematurely owing to the low 
benefit in relapsed CLL and manufacturers will not pursue further development [217]. 
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Anti-CD40 
CD40 is a transmembrane protein expressed on normal as well as malignant B cells. 
CD40L, produced by T helper cells and NK cells, appears to be coexpressed with CD40 in 
CLL cells. This finding suggests an autocrine loop in CLL which results in activation of 
PI3K as well as NKκB pathway and inhibition of apoptosis [217]. 
Lucatumumab is a fully human anti-CD40 antibody which triggers ADCC and inhibits 
CD40L induced proliferation in vitro [217]. However, phase I data in the relapsed setting 
showed mainly stable disease (SD) as best response [227]. 
 
Anti-CD19 
CD19 is a transmembrane protein with expression restricted to B cells and acts as a co-
receptor enhancing signaling in response to BCR antigen stimulation [217]. 
MEDI-551 is an anti-CD19 antibody which destroys CLL cells by ADCC. A phase II 
study evaluates safety/efficacy in advanced B cell malignancies (NCT 00983619). In 
combination with bendamustine MEDI-155 appears tolerable showing a different toxicity 
profile compared to rituximab with more infusion-related reactions but less neutropenia and 
nausea [228]. 
XmAb5574 is a humanized CD19 antibody with enhanced binding to FcγR. ADCC is 
mediated by NK cells through a granzyme B dependent mechanism [217]. A phase I study in 
CLL patients is completed but results are not yet published (NCT 01161511). 
Blinatumomab (MT103/MEDI538) is a so called bispecific T cell engager (BiTE). It is 
a mAb with specificity for both CD19 and CD3 and exerts its effect by tether resting  
T cells to CD19 positive CLL cells and cause tumor lysis [229]. High response rates were 
obtained in lymphoid malignancies but there are no clinical data in CLL. 
 
Anti-CD49d  
CD49d, an integrin with variable expression in CLL appears to be an important prognostic 
marker [102]. It plays a role in leukocyte migration, activation, survival and in leukocyte 
trafficking. In addition, activation of CD49d results in signaling which upregulated BCL-2. 
Natalizumab is an anti-CD49d mAb which has been shown to decrease migration of CLL 
cells in vitro [230]. However there are no clinical data in CLL yet. 
3.2 Small targeted molecules 
3.2.1 Targeting the B cell receptor and downstream SYK, LYN and BTK 
BCR activation is a central mechanism in CLL [43, 44]. The downstream activation of BCR–
associated kinases (LYN, SYK BTK and PI3Kδ) is also involved in other pathways such as 
chemokine and integrin signaling, cell adhesion and chemokine secretion [42, 48]. These BCR 
downstream kinases can be targeted by small molecule inhibitors (Figure 4a). 
 
SYK and LYN inhibitors 
SYK and LYN are non-receptor kinases activated upon BCR ligand binding. They activate 
signaling pathways downstream the BCR, and modulate cell adhesion and chemotaxis of  
B cells and are therefore critical for survival and maintenance [42, 46, 48]. 
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Fostamatinib is an orally reversible, relatively selective SYK inhibitor. In vitro its 
bioactive form is called R406. To date it is the only SYK inhibitor in clinical use. In a 
phase I/II clinical trial it was well tolerated and partial responses achieved [231]. An initial 
lymphocytosis was probably due to disrupted adhesion factors in the lymph nodes and bone 
marrow [232]. However, further development has focused on rheumatoid arthritis [42]. 
In vitro data on GS-9973, another SYK inhibitor, in combination with the PI3Kδ 
inhibitor idelalisib has indicated synergistic growth inhibition and reduced CCL3/CCL4 
production in CLL cells [233]. Clinical phase II data on this combination demonstrated that 
70% of patients had a > 50% reduction of lymph node size. However the study was 
terminated early due to the development of severe, steroid responsive, pneumonitis [234]. 
Early phase II data on single GS-9973 reported a > 50% reduced tumor bulk in 64% of the 
patients and the treatment was well tolerated even though reversible grade III and IV 
elevation of transaminases occurred in 4.5% [235]. 
Dasatinib is a reversible pan-Src kinase inhibitor which also inhibits a variety of other 
kinases such as LYN and BTK. In vitro data demonstrated inhibited BCR signaling and 
reduced survival of CLL cells as well as reduced chemotaxis and adhesion to stroma even 
in the presence of microenvironmental stimuli [42]. However, phase II data 
relapsed/refractory patients indicate modest results even in combination with fludarabine 
[236]. The low response rate compared to other kinase inhibitors targeting BTK or PI3Kδ 
might be due to the function of LYN as a negative regulator of BCR signaling [42]. 
Bafetinib (INNO-406) is an orally available LYN kinase inhibitor. When evaluated in 
relapsed and refractory CLL in the elderly there were no objective responses. A higher dose 
is under investigation [237]. 
 
BTK inhibitors 
Ibrutinib (PCI-32765) is the first human BTK inhibitor. It binds irreversibly and covalently 
to a cysteine residue of BTK (Cys481), which inhibits BTK’s enzymatic activity. Ibrutinib 
blocks BCR signaling in vitro [238] and in vivo [45] also inhibiting PLCγ2 and downstream 
signaling molecules (AKT, ERK). Both in vitro and in patients, ibrutinib impairs 
microenvironment-induced survival [238] and proliferation [50] as well as release of and 
migration towards tissue homing chemokines [50, 239, 240]. It also impairs integrin signaling 
and thereby CLL cell adhesion [239].  
The inhibition of adhesion/migration probably explains the CLL cell redistribution, 
seen with ibrutinib, which is characterized by a rapid and sustained decrease in 
lymphadenopathy accompanied by transient lymphocytosis [241, 242]. Lymphocytosis is 
asymptomatic, normalizes after a median of 6.2 months and the degree of it is not linked 
with response [243]. In vitro [50] as well as in vivo [45] data argues that BTK inhibition targets 
cell proliferation but ibrutinib has only a modest degree of apoptosis in vitro [50, 238]. Finally, 
ibrutinib might have an immune-modulating potential by affecting the repertoire of CD4+ 
T cells [244]. However this has to be explored further in future studies. 
Ibrutinib is given orally once daily at a fixed dose of 420 mg continuously until disease 
progression or toxicity. Ibrutinib achieved an ORR of 60%-71% with a median PFS of 13.6 
months and estimated 26 months PFS of 75% as a single agent in relapsed or refractory 
CLL [241, 245]. The OS was 83% at 26 months [245]. Response was independent of clinical and 
genomic risk factors with an ORR of 68% in cases with 17p deletion [245]. These results led 
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FDA to approve single-agent ibrutinib for relapsed CLL patients in February 2014. A phase 
III randomized trial compared ibrutinib with ofatumumab in relapsed/refractory CLL/SLL 
[246]. Responses, as assessed by response criteria specifically adapted for this trial and not 
the commonly used IWCLL criteria, were significantly more common with ibrutinib (43%) 
than with ofatumumab (4%). At a median follow-up of 9.4 months, PFS as well as OS was 
significantly improved with ibrutinib. For patients harboring 17p deletion median PFS in 
the ibrutinib arm was not reached as compared with 5.8 months in the ofatumumab arm. As 
first-line treatment ibrutinib monotherapy yielded an ORR of 71% with 13% CR in 
untreated elderly patients [247]. Combination therapies with ibrutinib are investigated to 
shorten the drug-induced lymphocytosis and to increase CR rates. Preclinical early data 
showed that a combination with anti-CD20 monoclonal antibodies might be less effective 
[248]. However, when investigated in patients with either 17p deletion or a short PFS after 
first-line, the combination of ibrutinib and rituximab achieved an ORR of 95% even though 
the CR rates were still low (8%) [240]. Combination therapy with ofatumumab or BR in non-
controlled trials in relapsed/refractory patients yielded response rates of 100% and 93% 
(including 17% CR) respectively [249, 250].The initial lymphocytosis appears less frequent 
with combination therapy [240, 249]. However, the relevance of clearing the peripheral blood 
remains unknown. Data on combination therapy from randomized trials is lacking but trials 
are ongoing (NCT 01611090 (ibrutinib-BR), NCT01886872 (BR vs ibrutinib-rituximab vs 
ibrutinib), NCT02048813 (ibrutinib in combination with rituximab vs FCR) and 
NCT01722487 (ibrutinib vs chlorambucil in elderly)). Phase III trials in the combination 
with obiniutuzumab are about to start soon. 
Ibrutinib is generally well tolerated as single agent and in combinations even in a 
heavily pretreated and elderly population with comorbidities [240, 245-247, 249, 250]. The most 
common AEs are ≤ grade II non hematologic toxicities (diarrhea, fatigue, nausea, myalgia 
and upper respiratory tract infection). Hematologic toxicity ≥ grade III is uncommon and 
infections ≥ grade III are rare [240, 245-247]. Adverse events of ≥ grade III usually include 
diarrhea and atrial fibrillation [246]. Atrial fibrillation of any grade might occur at a higher 
rate with ibrutinib [246]. Potential reasons for this are being explored. Serious bleeding, 
including subdural hematoma, not related to thrombocytopenia has also been observed [241, 
245]. Even though major bleeding was rare this led to current recommendations for 
avoidance of concomitant warfarin therapy and interruption of ibrutinib for 3-7 days before 
and after invasive procedures. Lower grade (≤ grade 2) bleeding-related AEs, most 
commonly petechiae, are frequent [245, 246]. Recent studies indicate that ibrutinib induces a 
dysfunction in platelet aggregation [251, 252] probably because BTK is a critical mediator of 
platelet signaling and collagen binding. 
Resistance to ibrutinib generally occurs in the context of Richter transformation and 
less commonly, in CLL progression [253]. Generally resistance involves mutation of the 
cysteine residue where binding occurs [254]. This mutation prevents irreversible drug binding 
leading to increased BCR signaling [255]. Another resistance mechanism is mutation in 
PLCγ2, immediately downstream of BTK, which potentially allow BTK independent BCR 
activation [254]. 
In summary, ibrutinib represents a promising drug in CLL. However, it does not seem 
to represent a “cure” as true CR [240, 245, 247] and MRD negativity appears rare [240] and 
continuous treatment seems to be needed. Furthermore, despite no significant difference in 
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response rates patients with 17p deletion appear to have weaker response as well as a 
shorter PFS [240, 245, 256-258] and most events associated with disease progression appear to 
occur in these patients [245, 247]. 
 
There are other BTK inhibitors in clinical trials. CC292 is an orally available, highly 
selective and irreversible inhibitor of BTK. It binds to the same cysteine residue as ibrutinib 
but is more specific. In a phase I study of relapsed or refractory CLL, it was well tolerated 
and the ORR was about 60% [259]. Even though not significant, patients with 17p deletion 
displayed a lower response rate (25%). 
ONO-4059 is also an orally available BTK inhibitor. It binds covalently to BTK and is 
more specific than ibrutinib. A recent phase I study of relapsed or refractory high risk CLL, 
ONO-4059 achieved an ORR of 90% (including modified PR with lymphocytosis) despite 
that the majority displayed TP53 disruptions [260]. ONO-4059 was well tolerated and no 
dose-limiting toxicities occurred. 
3.2.2 PI3K inhibitors 
Signaling from several major transduction pathways converge on PI3K which has a key 
role in regulating B-cell function and survival [48]. 
Idelalisib (CAL-101) is an orally available, highly specific and reversible inhibitor of 
PI3Kδ [261]. Idelalisib causes inhibition of AKT activation which decreases MCL-1 
(myeloid cell leukemia sequence 1) expression and promotes apoptosis in CLL cells in 
vitro as well as in patients  [262, 263]. Conversely, it shows minimal cytotoxicity against 
normal T and NK cells [262]. Idelalisib inhibits chemotaxis toward chemokines, pro-survival 
cytokines and secretion of chemokines (CCL3/4) from CLL cells in vitro as well as in 
treated patients [67, 262, 263]. Idelalisib also decreases CLL adhesion by interfering with 
CD49d/VCAM-1 binding [264] which might explain the redistribution of CLL cells observed 
in treated patients [163, 263]. Finally, idelalisib might have immune modulating capacity as 
inhibition of regulatory T cells has been shown in vitro [265]. 
The recommended maximum starting dose is 150 mg twice daily due to an observed 
plateau in plasma and consistent clinical response in lymph nodes with higher doses [263].  
A phase I study investigated idelalisib in heavily pretreated patients where 80% had bulky 
lymphadenopathy and 24% had TP53 disruptions [263]. No DLT were observed. The ORR 
was 72%, and median PFS was 15.8 months but patients who received a dosage of  
≥ 150mg twice daily showed a longer PFS than those treated with lower doses (31.9 vs. 6.6 
months). As single treatment in elderly previously untreated patients, idelalisib yielded 
objective responses in 96% (including CRs) and a 93% PFS rate at 24 months [266]. 
Preclinical data on idelalisib in combination with monoclonal antibodies is 
contradictive. Some in vitro data showed no interference with ADCC [262], while other 
suggests that idelalisib inhibits the cell-mediated effector mechanisms of CD20 monoclonal 
antibodies [248]. 
The only fully published combination study investigated rituximab combined with 
either idelalisib or placebo as part of salvage therapy [163]. The study was closed 
prematurely after 24 weeks at the first pre-specified interim analysis because the 
combination therapy demonstrated a significantly higher ORR (81% vs 13%), PFS rate 
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(93% vs 46%) and OS rate (92% vs 80%) at 12 months. Phase I data on combinations with 
either rituximab or ofatumumab showed similar response rates and a median PFS of  
26 months [267]. Idelalisib combined with rituximab or ofatumumab appears effective in 
patients harboring TP53 disruptions in untreated [266] and relapsed patients [267, 268]. In 
relapsed patients idelalisib monotherapy achieved an ORR of 54% and a PFS of 5 months  
in those with TP53 disruptions  compared to 72% and 41 months respectively for those 
without [263]. 
Idelalisib has shown to sensitize CLL cells for bendamustine, fludarabine and 
dexamethasone in stromal cocultures [67]. When combined with BR or chlorambucil the 
ORR was 90% with similar response rates in both cohorts [269]. Several studies evaluating 
combinations with BR (in first line as well as in the relapsed setting) or ofatumumab  
(NCT 01980888, NCT 01569295 and NCT 01659021) are ongoing. 
Idelalisib is generally well tolerated as monotherapy as well as in combination with 
mAbs or bendamustine [163, 263, 267, 269, 270]. The most common toxicities are non-hematologic 
≤ grade II (fatigue, rash, pyrexia and cough). However, several unique AEs have been 
reported. High rates (up to 30%) of pneumonia and pneumonitis have been observed. The 
mechanisms for these side effects remain unclear. Diarrhea, mostly ≤ grade II, has been 
reported in about 20-30% of the patients and may infrequently also be associated with 
colitis [163, 263, 266]. Hepatic transaminitis is the third side effect requiring special attention. It 
has not resulted in clinically significant liver dysfunction and upon drug withdrawal it 
seems to improve rapidly [163, 263, 266]. However, close monitoring of serum transaminases 
appears important. Adverse reactions necessitating discontinuation of treatment have most 
frequently been hepatotoxicity and/or diarrhea/colitis [163, 263, 266].  
Preclinical data showed a synergistic effect of the combinations of idelalisib and  
GS-9973, a SYK inhibitor [233]. However, one clinical trial was terminated early due to the 
development of severe, steroid responsive, pneumonitis [234].  
Idelalisib was approved by FDA 2014 for relapsed CLL as a single agent and in 
combination with rituximab in patients for whom rituximab alone would, according to US 
therapeutic traditions, be considered an appropriate therapy. Idelalisib is approved in the 
EU in combination with rituximab for patients who have received at least one prior therapy; 
or as first-line treatment in patients with TP53 disruptions unsuitable for 
chemoimmunotherapy. 
In summary, idelalisib appears to be active in high-risk patients. It is generally well 
tolerated but is associated with certain side effects that require special attention. Preclinical 
data indicates that idelalisib might be a treatment to explore further in patients with 
progressive disease during ibrutinib treatment [255]. 
Another PI3K inhibitor, IPI-145 (INK-1147) is currently investigated in CLL. It is an 
orally available PI3K inhibitor inhibiting both the δ and γ isoforms. Results from a phase I 
study in patients with advanced CLL showed an acceptable safety profile [271]. The ORR 
was 52% (including CRs) and patients with TP53 disruptions had similar response rate.  
A transient treatment-related lymphocytosis along with decreased lymphadenopathy was 
observed. The most common side effects were transient neutropenia and elevated 
transaminases. A phase III study of IPI-145 versus ofatumumab in relapsed refractory 
patients (NCT 02004522) as well as combination studies with FCR or BR (NCT 02158091 
NCT 01871675) is currently ongoing. 
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3.2.3 BCL-2 inhibitors 
BCL-2 family members contribute to CLL cell survival. It includes more than 20 members 
with either anti-apoptotic or pro-apoptotic activity. The anti-apoptotic proteins (BCL-2, 
BCL-xL, MCL-1) share sequence motifs termed B1 to B4. The pro-apoptotic proteins are 
divided into two subgroups where the first group (BAX (BCL-2 associated X protein) and 
BAK (BCL-2 antagonist/killer 1)) displays three BH3 domains and the second group (BIM, 
BAD) shares sequence homology only with the BH3-domain (BH-3 only proteins). 
BAX/BAK leads to the formation of pores resulting in mitochondrial outer membrane 
permeabilization (MOMP) and apoptosis. BH3-only proteins act as activators of 
BAX/BAK by displacing them from being bond to anti-apoptotic proteins The anti-
apoptotic proteins (BCL-2, BCL-xL, MCL-1) bind the BH3 domains of pro-apoptotic 
proteins thus preventing activation of BAX/BAK [272]. Many pro-apoptotic BH3-only 
proteins are TP53 transcriptional targets, thus this balance appears even more skewed 
toward survival in CLL cells with defect TP53 [273]. Inhibiting anti-apoptotic BCL-2 
proteins might be a way to tip the balance between survival and apoptotic signals and to 
circumvent a requirement for functional TP53. 
BH3 mimetics (Figure 4c) are small molecules which bind to anti-apoptotic inhibitors 
thereby allowing the pro-apoptotic activity of BH3-only molecules. Navitoclax (ABT-263) 
is an orally available BH3-mimetic, targeting preferentially BCL-2 and BCL-xL proteins. 
As monotherapy in relapsed/refractory patients in a phase I study it yielded 35% PRs and 
was equally effective in patients harboring 17p deletion [274]. Dose-dependent 
thrombocytopenia was the dose-limiting event and many patients did not tolerate adequate 
drug concentrations. This side effect was somehow expected since BCL-xL is the primary 
survival factor in platelets and preclinical data show that inhibition of BCL-xL has caused a 
dose dependent thrombocytopenia [275]. Early phase I data on navitoclax in combination 
with BR showed promising results (ORR up to 81% including CRs) [276]. The study has 
been completed (NCT 008 68413) but is to date not published. 
ABT-199 (GDC-0199) is a very specific BCL-2 inhibitor with higher affinity to  
BCL-2 compared to BCL-xL [61]. ABT-199 inhibits growth of BCL-2 dependent tumors in 
vivo and, consistent with its lower BCL-xL inhibition, spares platelets [61]. A recent phase I 
study of ABT-199 in relapsed/refractory patients reported an ORR of 77% with a CR rate 
of 23% and with a 2 year PFS of 59%. The response rates in high-risk patients were similar 
and MRD-negativity was observed in several patients achieving CR, including those with 
17p deletion [277]. The DLT has been hyperacute, TLS but it seems to be manageable by 
using a ramp-up dosing scheme combined with aggressive prophylaxis and monitoring [277]. 
Neutropenia was the most common severe (≥ grade III) side effect, affecting at least 
one third, however febrile neutropenia was not frequent (6%). Non-hematological side 
effects (diarrhea, nausea and fatigue) affected about one third of patients [277, 278]. 
Early data from a phase Ib study of ABT-199 in combination with rituximab in 
relapsed/refractory patients showed objective responses in 84% including 36% CRs as well 
as observed MRD negativity [278]. The combination appears well tolerated with no new 
toxicities identified. However, a case of fatal TLS amended the dosing regimen. 
Further trials with ABT-199 as a single agent as well as in combinations are ongoing. 
(NCT 01889186 phase III study of ABT-199 in relapsed/refractory patients harboring 17p 
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deletion and NCT 02005471 phase III study of ABT-199 combined with rituximab vs BR 
in relapsed /refractory patients). 
3.2.4 CDK inhibitors 
Cyclins are important regulators of the cell cycle. Normally their expression fluctuates 
regularly and they require the presence of a cyclin-dependent kinase (CDK) to do their 
regulatory work. There is a large variety of cyclins and CDKs involved in cell cycle 
progression where some play key roles in RNA transcript production of anti-apoptotic 
proteins [279]. CDKs can be targeted by several inhibitors and the inhibition results in a 
decrease of anti-apoptotic proteins, and thereby induction of programmed cell death in CLL 
cells in a p53-independent way  [280, 281]. 
The broad CDK inhibitor flavopiridol (alvocidib) is the most comprehensively studied 
compound in this category of drugs. In early clinical trials it induced an ORR of 45-53% 
with similar response rates in patients with 17p deletion and/or bulky lymphadenopathy [282, 
283]. In combination with rituximab higher response rates were achieved but this study 
included other lymphomas as well [284]. A study investigating the combination with 
lenalidomide is ongoing (NCT 00735930). As flavopiridol is a broad inhibitor targeting 
several CDKs its therapeutic window is narrow. A dose escalation approach seems to be 
needed since the limiting factor in clinical trials have been acute TLS [282, 283]. 
The pan-CDK inhibitor dinaciclib (SCH 727965) has shown potent pre-clinical activity 
against CLL cells independently of high-risk genomic features by downregulating 
messenger RNA and protein expression of MCL-1 [281]. However, it appears ineffective at 
overcoming the protective effect between CLL cells and stromal cells [281]. Dinaciclib 
achieved an ORR of 58% and a PFS of 16 months  in patients with relapsed or refractory 
CLL in a phase I/II trial [285]. The ORR for patients with 17p deletion was similar (57%). 
P1446A is a novel orally active CDK inhibitor which has shown pre-clinical activity in 
CLL. However, samples carrying 17p deletion showed decreased sensitivity [286].  
Pre-clinical data on CDKI-73, a CDK9 inhibitor, showed higher induction of apoptosis 
compared to flavopiridol [287]. It was equally effective in cells from high-risk patients and 
showed synergy with fludarabine. This makes CDKI-71 interesting for further exploration. 
The most frequent related toxicity appears to be myelosuppression and the associated 
increased risk of tumor lysis syndrome [282, 283, 285].  
In conclusion, CDK inhibitors appear effective both as single agents and in 
combination with chemotherapy in relapsed and refractory CLL, including cases with TP53 
disruptions. However recent limited retrospective data analysis showed that ibrutinib 
surpassed CDK inhibitors both at inducing response and prolonging median PFS and OS 
[256]. Still, both ibrutinib and CDK inhibitors were more effective than other standard or 
investigational regimens. Therefore the place of CDK inhibitors remains to be defined. 
3.2.5 HDAC inhibitors 
Histone deacetylases (HDACs), in several isoenzyme classes, are overexpressed in CLL 
[288, 289]. HDACs mediate the epigenetic silencing of certain miRNAs which are critical 
tumor suppressors. Inhibition of HDACs in vitro has been shown to induce expression of 
these miRNAs followed by a declined level of MCL-1 and induction of cell death [289] i.e. 
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HDAC inhibitors have the ability to reverse epigenetic alterations associated with CLL cell 
survival (Figure 4c). These results suggest that patients exhibiting epigenetic silencing may 
benefit from HDAC inhibitors. HDAC inhibitors may also induce autophagy, a “self-
eating” process, which is a pro-apoptotic mechanism in CLL [290]. 
Mocetionstat (MGCD0103) is an orally available HDAC inhibitor that demonstrated 
efficacy in vitro in human cancer cell lines [291]. It modulated the expression of critical 
autophagy genes which  possibly contributes to autophagy impairment in CLL cells  [290]. 
However, the clinical effectiveness in CLL appears to be limited, with no responses in a 
phase II trial in CLL high-risk patients [292]. Since HDAC isoenzyme levels in CLL may be 
of more than one class [288] a combination of therapies [293] or a broader targeting was 
thought to be needed to get a clinical effect. However, treatment with the pan-HDAC 
inhibitor vorinostat did not result in clinical responses [294]. 
3.3 Other immunotherapy 
One of the paramount ways malignancies establish themselves is through suppressing both 
the innate and acquired immune systems. In CLL effective antitumor immune responses are 
lacking due to the capacity of the malignant cells to induce a state of profound immune 
dysfunction [109]. 
Circumventing this with allogeneic stem cell transplantation can be effective but is also 
associated with high morbidity and mortality [213]. Strategies to restore autologous antitumor 
immune responses, also tolerable for the elderly, are emerging. These strategies interfere 
with either inhibitory signaling axes or CLL cell stimulating niches. 
3.3.1 Lenalidomide 
Lenalidomide belongs to the immunomodulatory class of drugs. Its mechanism of action 
appears disease specific and since it is not directly cytotoxic in vitro [295], its clinical activity 
in CLL has been presumed to be secondary to its immune modulating activity. 
Lenalidomide improves T cell function by; repairing the functional synapse defects of 
T cells, downregulating expression of T cell inhibitory molecules (such as PD-1) and 
enhancing T cell motility [128, 129, 296-298]. In addition, lenalidomide inhibits Tregs and 
normalize functional T cell subsets and induces T helper (Th17) cells [299, 300] which further 
antagonizes inhibitory signaling axes. 
Lenalidomide has important direct effects on CLL cells as well. In vitro, CLL cells 
appear to be activated as they express higher levels of immunostimulatory molecules 
(CD80, CD86, HLA-DR, CD95 and CD40) and lower levels of inhibitory molecules [301-
303]. This might enhance their capacity to engage T cells in cognate interaction and maybe 
lead to immune activation by tumor associated antigens. Lenalidomide may also reverse 
hypogammaglobulinemia by upregulation of CD154 on CLL cells which in turns may co-
stimulate normal B cells to produce antibodies [302]. Further, B cells treated with 
lenalidomide showed to downregulate the expression of PD-L1 thereby possibly reducing 
the inhibitory impact on T cells [129]. NK cells appear to be affected as well showing 
enhanced cytotoxicity [128]. Moreover, treatment with lenalidomide appears to affect the 
levels of cytokines, such as IL-2, IFNδ and TNFα [299, 304] and in vitro lenalidomide appears 
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to reduce the survival support from nurse-like cells and to modulate the migratory potential 
of CLL cells (Figure 4d) [305]. 
Even though the major effects of lenalidomide in CLL might be through the 
microenvironment new data suggest a direct antiproliferative effect [306]. Lenalidomide 
binds cereblon, a component in a complex responsible for target recognition and binding of 
proteins to be degraded. This results in increased expression of the CDK inhibitor 
p21WAF1/Cip1 (p21), a negative regulator of cell cycle progression, leading to cell cycle 
arrest. Lenalidomide is also suggested to promote an enhanced cereblon-mediated 
degradation of transcription factors (Ikaros and Aiolos,) thereby enhancing T-cell and NK-
cell activation and function [307]. However additional studies are required to evaluate 
whether this is a mechanism of action in CLL. Altogether, lenalidomide represents one of 
the few immune restorative therapeutics used in CLL and may be of special interest since 
its function appears p53-independent. 
As a single agent, lenalidomide induced objective responses in 32% - 47% in heavily 
pretreated patients with relapsed or refractory CLL [304, 308]. When further developed as 
initial treatment for elderly patients [298, 309] response rates of up to 65%, including 10% 
CRs, were reported, with an OS of 86% at 4 years follow up [310]. However, a randomized 
controlled trial (NCT 00910910) comparing the safety and efficacy of lenalidomide versus 
chlorambucil as first-line therapy for elderly patients was recently halted by FDA because 
of significant safety concerns due to an imbalance in the number of deaths in lenalidomide-
treated patients [311].  
A previous study reported that lenalidomide could reduce CD20 expression in vitro 
and thereby maybe mitigate the activity of rituximab if given in combination with 
lenalidomide [312]. However, another study reported that lenalidomide enhanced NK-cell 
mediated ADCC in relation to rituximab treatment  [313]. In clinical trials with previously 
untreated or relapsed patients, the combination of rituximab and lenalidomide achieved 
response rates of 88% and 66% (including 15% and 12% CR) respectively [303, 314]. The  
estimated 3 year OS, in relapsed/refractory patients, was 71% [314]. The median PFS in the 
first line setting was 19 months being similar to median time to treatment failure in the 
relapsed/refractory patients (17.4 months). PFS was longer in patients who achieved CR 
but elderly patients did not display any shorter PFS/time to treatment failure. In addition, 
only a modest decline in CD20 levels was observed after lenalidomide monotherapy [303]. 
Lenalidomide combined with ofatumumab in relapsed/refractory patients yielded an 
ORR of 48%, all PR, and a median OS of 21.5 months [315]. Another study of the same 
combination with a more intense schedule is ongoing and early data indicate response rates 
of 68% including 24% CR [316]. 
Even though lenalidomide appears to act in a p53 independent manner the ORR with 
lenalidomide monotherapy was only 31% in relapsed/refractory patients with 17p deletion 
[304] and when lenalidomide was used as initial treatment in elderly there was no responses 
in this group of patients  [309]. In a preliminary report from a study comparing lenalidomide 
single to lenalidomide plus rituximab 17p deletion was significantly associated with 
inferior survival [317]. However, early results from a phase II trial investigating single agent 
lenalidomide in relapsed/refractory patients with or without TP53 mutations showed similar 
outcomes in both groups [318]. 
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There are some troublesome side-effects with lenalidomide of which the most notable 
ones are specific for CLL. TLS, resulting in some deaths, was reported when the starting 
dose was 25 mg [308] but did not occur when the starting dose was lowered to 10 mg in the 
relapsed/refractory setting. However, TLS was observed in treatment-naïve patients [298] and 
this prompted an even more careful approach with starting doses of 2.5 mg. Prophylaxis 
with allopurinol, hydration and careful laboratory monitoring together with a low starting 
dose followed by slow dose escalation has successfully mitigated the risk of TLS. The 
MTD of lenalidomide remains unclear. 
Tumor flare reaction (TFR) manifested by acute swelling of involved lymph nodes 
sometimes associated with fever, localized erythema or rash is a side-effect occurring in 
CLL patients  [319]. Onset may start within hours after the first dose and even if observed 
more frequently during the first cycle, it may be recurrent for months [298]. TFR is 
associated with upregulation of CD40, CD80 and CD86 on CLL cells as well as T-cell 
activation [301]. First-line studies reported higher rates of TFR (52-88%) [298, 309] than studies 
in relapsed patients [304, 308]. This might suggest a greater tendency for immunostimulation in 
treatment-naïve patients. For patients treated according to a dose-escalation schedule TFR 
is usually of low grade if it occurs and manageable with nonsteroidal anti-inflammatory or 
steroid therapy  [298, 303, 314]. TFR has been associated with response but data is contradictive 
[303, 315, 319]. Neutropenia is the most common hematologic adverse event and even on low 
doses the incidence of severe (≥ grade III) neutropenia is up to 83% [298, 303, 304, 308, 309, 314]. 
Severe thrombocytopenia is less common (up to 45%). Non hematologic toxicity such as 
fatigue, gastrointestinal symptoms and skin rash is predominantly of low grade (I-II) if an 
appropriate dosing schedule is applied [303]. The increased risk of thromboembolism 
described in first studies appears to be manageable with aspirin prophylaxis [298, 303, 304, 308]. 
In summary, the clinical efficacy of lenalidomide in CLL appears to include both  
T-cell antitumor immune responses and increased CLL cell “visibility” to the activated 
immune system as well as cytostatic mechanisms. Lenalidomide has clinical activity in 
CLL as single agent [298, 304, 308, 309] as well as in combination with rituximab [303, 314]. Side-
effects are manageable but require special attention. As consolidation after chemo-
immunotherapy, it appears to result in improved quality of remissions as well as prolonged 
time to salvage therapy [297]. In line with previous studies this shows that deeper responses 
appear to require a long duration of therapy [298, 314]. However, patients with 17p deletion 
appear to benefit less [309, 310, 314] and the place for lenalidomide in treating patients with 
TP53 disruptions is currently unclear. 
3.3.2 CAR-T cells 
Cure is achievable by breaking immunological tolerance in the context of ASCT. This 
underscores the powerful therapeutic effect of the T cell immune response in eliminating 
CLL cells [212, 213]. Another approach to circumvent tolerance to tumor-associated antigens 
is to modify the patient’s own T cells to target the malignant cells (Figure 4d). This offers 
an opportunity to produce a GVL without GVHD. In addition, ex vivo manipulation of  
T cells outside the inhibitory microenvironment may also offer a possibility to reverse the 
T-cell dysfunction. This has been achieved by the use of the single-chain variable fragment 
form an antibody molecule fused with an internal signaling domain such as CD3ζ to from a 
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chimeric antigen receptor (CAR). CAR-T cells may redirect the immune responses through 
their immune receptors with tumor associated antigen specificity. Genetic manipulation of 
T cells for introduction of a CAR transgene often relies on transduction using recombinant 
retrovirus but non-viral approaches such as electroporation have been investigated [320].  
A non-viral approach has the advantage of limiting the theoretical risk for insertional 
mutagenesis, causing autonomous T cell proliferation. However, no genotoxicity has been 
apparent so far [320]. The optimal design of CAR-T cells remains to be determined. First 
generation CARs were activated only through CD3ζ but problems with in vivo persistence 
and thus anti-tumor effect led to development of second generation CAR-T cells containing 
a co-stimulatory molecule, such as CD28, in addition to CD3ζ thus enabling CAR-T cells 
to respond to and kill CLL cells despite lack of costimulatory molecules on the malignant 
cells [321]. Third generation CAR-T cells contain three signaling domains. The most 
commonly targeted tumor-associated antigen in CLL is CD19 which is a suitable target 
since it is only expressed on B-cells and is not shed into the circulation [320]. Other antigens, 
for instance ROR-1, are explored in trials. 
Anti-CD19 CAR-T cells have shown impressive early results in CLL. The first trial 
treated 3 patients with relapsed/refractory CLL [322]. All patients responded (2 CR and 1 PR) 
despite bulky lymphadenopathy (3/3) and 17p deletion (2/3). In a recent update 14 
relapsed/refractory patients of whom 6 had 17p deletion have been treated. The ORR after 
a median follow-up of 9.4 months was 57% (21% CR) [323]. Responses were independent of 
age, number of prior therapies and TP53 abnormalities and there does neither seem to be a 
dose:response nor a dose:toxicity relationship at the dose ranges of CAR-T cells used so 
far. The CAR-T cells expanded in vivo were able to persist for at least 3 years [323, 324].  
Most patients with an anti-tumor effect experienced infusion-related toxicity (fever, 
hypotension and occasionally, deterioration in mental status and neurological changes). 
These side-effects seem to arise from the synchronous activation of infused CAR-T cells by 
bulky deposits of CD19+ CLL cells leading to a surge in cytokines, such as TNF and IFNγ, 
and activation of macrophages [322, 323]. In addition, clinical management can be complicated 
by TLS. Anti-inflammatory agents and systemic steroids must be dosed to mitigate toxicity 
without immediately compromising the anti-tumor effect mediated by CAR-T cells. To 
avoid these toxicities patients should probably have a reduced tumor burden before infusion 
of CAR-T cells. So far the vast majority have received chemotherapy prior to infusion 
which also might be a way to achieve better responses [323]. An effect of undesired on-target 
toxicity was the elimination of normal B cells and profound lymphocytopenia [324]. Patients 
probably benefit from intravenous immunoglobulin until B-cell immunity recovers. 
Reasons for CAR-T cells failure is not completely understood but may be related to 
downregulation of tumor associated antigens, or inability of CAR-T cells to recycle 
effector functions which may be due to an influence from tumor microenvironment [320]. 
Many challenges remain including better efficacy, acceptable toxicity and ability to 
produce CAR-T cells in a large commercial scale thus providing a more favorable cost 
profile, and to achieve good efficacy with acceptable toxicity. 
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3.3.3 Targeting the CXCR4 –CXCL12 axis 
The stromal cell-mediated drug resistance may, at least partly, be reversed by CXCR4 
antagonists who inhibit CLL cell activation by CXCL12 [48]. Plerixafor, is a selective, 
reversible inhibitor of the chemokine receptor CXCR4. It inhibits CXCL12-mediated 
chemotaxis and binding. It is approved by FDA in lymphoma and multiple myeloma for 
mobilization of HSC [48]. Early phase II data from relapsed CLL patients treated with 
plerixafor in combination with rituximab demonstrated a dose-dependent mobilization of 
CLL cells from tissues into the blood as well as some responses [325].  
An alternative approach is to target the chemokine CXCL12 (the ligand of CXRC4). 
NOX-A12 is an RNA oligonucleotide that binds and neutralizes CXCL12. It effectively 
inhibits CXCL12 induced chemotaxis of CLL cells and enhances their sensitivity to 
fludarabine and bendamustine in preclinical models [326]. A phase IIa clinical trial evaluates 
NOX-A12 in combination with BR in relapsed CLL (NCT 01486797). 
3.3.4 PD-1/PD-L1 axis 
An important mechanism for the failure of immune responses in CLL appears to be the 
suppression by inhibitory pathways. PD-1 is an inhibitory receptor predominantly 
expressed on exhausted T cells. After binding its ligand PD-L1, PD-1 inhibits the T cell 
receptor-mediated lymphocyte proliferation and cytokine secretion. In the normal setting 
this is an important function for maintenance of peripheral tolerance [127]. In CLL T cells 
and CLL cells display an increased expression of PD-1 and PD-L1 respectively [327]. CLL  
T cells show enhanced expression of PD-1 [127]. PD-1 appears involved in tumor-mediated 
immunosuppression by binding its ligand PD-L1. T cells in CLL patients display increased 
expression of PD-1 and CLL cells have an increased expression of PD-L1 [327]. Blockade of 
this interaction might restore the function of anergic T cells. Results in solid tumors with 
PD-1 blocking have been promising [328]. However, there are few clinical trials in 
hematological malignancies. Phase I data on an anti-PD1 antibody in CLL showed SD but 
no CR/PR [329]. 
3.3.5 CD200 
CD200 is a transmembrane IgG cell surface ligand that functions as a negative immune 
regulator. By blocking the interaction between CD200 and its ligand the tolerance to tumor 
antigens might be prevented [330]. CD200 is upregulated in CLL is used as a marker to 
distinguish CLL from mantle cell lymphoma [331] and plasma levels of CD200 appeared 
elevated in CLL patients compared with healthy controls and plasma levels were 
significantly correlated with CLL disease stage [332]. Preclinical data indicates that CD200-
blockade stimulates T cell responses against CLL cells and decreases the number of Treg  
[333]. However, to date clinical data in CLL are limited. 
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4 AIMS OF THE THESIS 
The aims of this thesis are to gain a deeper insight into the outcome of patients with 
advanced-phase chronic lymphocytic leukemia (CLL) and to explore new emerging drugs. 
  
More specifically: 
I. To obtain routine clinical practice outcome data on consecutive chemotherapy-
refractory CLL patients from a well-defined geographical region. 
 
II. To obtain knowledge about the efficacy and safety of alemtuzumab in 
previously treated consecutive patients with advanced CLL when used in 
routine health care at experienced centers in a defined region, and to compare 
the results with those from multicenter trials and other previous reports. 
 
III. To study safety of lenalidomide and alemtuzumab in combination therapy and 
to examine whether low-dose lenalidomide could stimulate and maintain 
immune functions in very advanced-phase CLL patients prior to and during 
therapy with alemtuzumab. 
 
IV. To examine, in a manufacturer-independent analysis, the in vitro sensitivity of 
CLL cells to a panel of small targeted therapeutic molecules and whether there 
is a difference in their individual in vitro cytotoxic capacity and between 
patients with progressive or indolent CLL and also to study associations 
between clinical characteristics and in vitro drug sensitivity. 
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5 MATERIAL AND METHODS 
5.1 Evaluation of response and toxicity 
Response evaluation of CLL therapy (Paper I, II and III) was performed using the IWCLL 
guidelines response criteria [113]. In paper II we compared with the NCI-WG criteria [334]. 
Adverse events were graded according to the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0. In Paper I and Paper II 
only AEs ≥ grade III were recorded, with the exception of CMV reactivations and herpes 
infections, which were always recorded even those considered ≤ grade II. 
5.2 Definition of refractory CLL 
Fludarabine refractoriness was defined as failure to achieve at least PR following a 
minimum of one cycle (if progression on therapy, otherwise at least two cycles were 
required) of fludarabine-containing regimen or disease progression within 6 months of 
completion of therapy. Bulky nodal disease was defined as lymphadenopathy with lymph 
node(s) ≥ 5 cm in largest diameter, assessed by physical examination or CT scan. 
Alemtuzumab refractoriness was defined as failure to achieve at least PR following a 
minimum of 12 doses of alemtuzumab, or disease progression within 6 months of 
completion of therapy. 
5.3 Study procedures 
5.3.1 Paper I and II 
The Regional Cancer Registry in Stockholm was used to identify all patients diagnosed 
with CLL year 1991-2010. Their medical files were reviewed to identify a) those being 
refractory to fludarabine, including those who in addition were BFR or DR and b) those 
treated with alemtuzumab in the relapsed or refractory setting. The medical records were 
reviewed commencing from the date of first diagnosis until death or until the end of the 
study period (April 2010), whichever came sooner. Demographic and treatment outcomes 
were recorded in CRF. A record of death was validated against the Swedish Cause of Death 
Registry [335]. In Paper I patients with fludarabine refractory CLL were further classified 
into 3 subgroups for subsequent analyses: BFR, DR and a non-BFR/DR group consisting of 
patients who were refractory to fludarabine but never met the criteria for BFR or DR. 
Patients in the DR and BFR groups were further divided into 2 smaller subgroups, 
depending on whether or not they matched all the inclusion criteria stipulated for a pivotal 
ofatumumab trial [206] (this agent was approved by EMA on phase II study results without a 
control group). In Paper II patients were considered evaluable for safety/efficacy of 
alemtuzumab if they had relapsed/ refractory CLL and had received at least one dose of 
alemtuzumab. Both intravenous and subcutaneous administrations of alemtuzumab were 
included. Patients were classified into three subgroups for subsequent analyses. Those who 
were refractory to purine analogues comprised the Refractory Group. Those who had 
relapsed after treatment with purine analogues but not fulfilling the refractory criteria 
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comprised the Purine analogue relapsed Group. Finally, those who relapsed after treatment 
with agents other than purine analogues comprised the Relapsed/Other Group. 
5.3.2 Paper III 
Consecutive patients diagnosed with refractory CLL or considered inappropriate for 
fludarabine-based therapy were included. Adequate organ function was required and 
patients had to have a performance status of ECOG score ≤ 2. All patients had viral and 
bacterial prophylaxis and, if needed, G-CSF. Lenalidomide alone was given weeks 1-4 
according to a stepwise dose escalation schedule with a starting dose of 2.5 mg/d. Week 5 
alemtuzumab s.c. was added and the combination was given for 12 weeks. Patients were 
regularly monitored regarding TFR and TLS. Immunomonitoring was performed at 
baseline, at the end of the first cycle, i.e. week 4, and at the end-of treatment. 
5.3.3 Paper IV 
Blood samples were acquired in connection with routine tests from consecutive CLL 
patients at the Department of Hematology, Karolinska University Hospital.  
Patients were classified into 2 groups; indolent CLL, with no treatment indication, and 
progressive, symptomatic CLL, requiring treatment irrespectively of previously treated or 
untreated [113]. Some patients with progressive CLL also provided bone marrow samples 
5.4 Laboratory methods  
5.4.1 Paper III 
Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood by using Ficoll 
gradient density separation. PBMC were used for the subsequent experiments which 
included flow cytometry and T-cell response to purified-protein-derivative of tuberculin 
(PPD) and phytohaemagglutinin (PHA). 
The PBMC for flow cytometry were mixed with appropriate amount of antibodies; 
CD4, CD8, CD3, CD16 & CD56 in prospective tubes for surface staining. After washing 
and permeabilization of the cells, perforin & granzyme B were added and incubated for 30 
minutes. Foxp3 staining was performed using a Treg staining kit. After a final wash, cells 
were resuspended in PBS (phosphate buffered saline) and run by LSR11 flow cytometer. 
All data were analyzed using the FlowJo software .Expression of activation markers 
(CD154, CD28, CD25, CD69, CD40, HLA-DR), co-stimulatory molecules (CD80, CD86), 
proportions of memory and naïve T cells (CD45RA, CCR7), apoptosis molecules (Fas-L, 
CD95) and chemotaxis (CXCR4) as well as CD38, CD52, CD83, CD95 and CD16 were 
also evaluated. 
For the functional tests, semi-purification by nylon wool separation of PBMC was 
made if the number of lymphocytes was > 10x109 /ml in the sample. The T-cell response to 
PPD and PHA was assessed during a 5 day culture system on microtiter plates where  
6 wells were loaded with PPD 5 µg/ml and PHA 10 µg/ml respectively. Each well was 
loaded with 100 µL cell suspension containing approximately 200 000 cells in cell culture 
medium (RPMI (Roswell Park Memorial Institute) + 10% AB+ serum). As controls, 6 wells 
were loaded with PBMC alone. During the last 18 hours of incubation, 1µCi/well 
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thymidine was added and incorporated radioactivity was measured by Wallac 1450 
MicroBeta® TriLux. Results were displayed as ΔCPM, calculated mean radioactivity 
(CPM) of 6 replicates of experimental wells subtracted by the background value (cells with 
medium alone), and as stimulation index (SI) calculated by mean CPM divided by the 
background value. 
5.4.2 Paper IV 
Laboratory methods are described in detail in Paper IV. Briefly, blood and bone marrow 
samples were collected in EDTA- or heparinized glass tubes and immediately transported 
to the laboratory. The blood was diluted with PBS and PBMC were isolated using Ficoll 
gradient density separation. The drug sensitivity of primary CLL cells was assessed using a 
72h cell culture system (in vitro viability (iVV) assay) on 2 different 384-well microtiter 
plates loaded with 31 small therapeutic molecules and 29 cytostatic agents. The killing-
capacity of each drug was measured at 4 different concentrations in triplicate. Each well 
was loaded with 30 µL cell suspension containing approximately 4000 cells in a primary 
cell culture medium (OmniSanguine, Qantascope Biotech, Stockholm, Sweden) which 
mimics the in vivo environment. Two types of controls were used on each plate, wells 
containing culture medium alone and wells containing culture medium and PBMC but no 
drug. 
To verify the robustness of the system, cells were also analyzed after 24 and 48 hours 
and an additional analysis where CLL cells from the same patient were cultured in both 
OmniSanguine and RPMI medium was made. 
After 3 days of incubation, live and dead cells were differentially stained by 
fluorescent VitalDye. An automated digital fluorescent scanner HexascopeHaema 
quantified the precise number of living and dead cells. The image capturing control 
software, the digital image analysis software package and the clinical report generating 
computer program was applied as previously described [336]. The assay has been validated 
on CLL cells using conventional cytostatics [336] and received a European in vitro 
diagnostical approval (IVD) for Europe in July 2014. 
The 31 small molecules were obtained from a single distributor to ensure comparable 
quality. The drugs were either in clinical use or in early clinical/preclinical testing. An 
equimolar concentration range was applied for the small targeted molecules in order to 
optimize head-to-head comparison. 
As controls, 29 cytostatic agents were tested in the same way as previously described, 
where the drug concentration was selected by approximating from concentrations achieved 
in vivo [336]. 
The drug sensitivity was calculated as a single value of killing efficiency (KE%) from 
triplicate measurements at four different dilutions after 72 hours of incubation. KE%, a 
value graded from 0 to 100, was calculated for each drug and is a weighted sum of dose 
dependent killing-capacity. A comparison of KE% in OmniSanguine and RPMI was made 
as well. 
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5.5 Statistical analysis 
5.5.1 Paper I and II 
The Kaplan-Meier method was used to calculate survival from the start date of first salvage 
therapy (Paper I) or alemtuzumab therapy (Paper II) to the date of death or date of last 
follow-up and from the date of diagnosis of CLL to the date of death or last follow-up. 
Patients who received an ASCT after salvage therapy/alemtuzumab therapy were not 
included in survival analysis. In Paper II, the Landmark method [337] was used to calculate 
survival as well. Differences in survival distributions were compared using the log-rank 
test. Categorical and continuous data were compared using the Fisher’s exact and χ 2 tests 
(Paper I), as appropriate and using Fisher’s exact and Wilcoxon rank-sum test (Paper II), as 
appropriate. Cox regression analysis was used for univariate and multivariate models of 
survival while log-rank test was used to test for equality over strata. All reported p values 
were two-sided. 
5.5.2 Paper III 
Wilcoxon signed-rank test for paired samples was used for comparison between the 
baseline and end of treatment of laboratory values. Spearman correlation was used for the 
dose-dependent reduction of relative proportion of Treg in the CD4+ T cell population 
during cycle 1. All reported p values were two-sided. 
5.5.3 Paper IV 
Independent two-sample t test was used to compare drug response and clinical data 
between patient subgroups and survival between OmniSanguine and RPMI medium. 
Cluster analysis with laboratory (KE%) and clinical data using custom developed analysis 
and visualization. Heatmaps were generated using custom built plugins in ImageJ [338]. 
Discontinuous clinical data were represented by defined values on a 0-100 scale. Binary 
categories were represented by 0 and 100 respectively whereas discrete categories (e.g. Rai 
or Binet stage) were shown by values normalized for hundred grade scale. Hierarchical 
clustering was done using Euclidian distance and complete linkage. Pearson´s correlation 
coefficient was calculated for every drug sensitivity and clinical data. All reported p-values 
were two-sided. 
5.6 Ethical aspects 
All studies were approved by the Regional Ethics Review Committee (www.epn.se). As 
Paper I and II were retrospective observational studies no informed patient consent was 
required. Patients participating in studies reported in Paper III and Paper IV provided 
informed consent. The study reported in paper III was performed in accordance with Good 
Clinical Practice (GCP) and studies reported in Paper III and Paper IV were performed in 
accordance with Guidelines on Good Laboratory Practice (GLP). 
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6 RESULTS, DISCUSSION AND CONCLUSIONS 
6.1 Paper I 
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia 
– a population-based study from a well-defined geographic region  
Eketorp Sylvan et al. Leukemia & Lymphoma, 55(8):1774-80, 2014 
The natural history of advanced CLL in a well-defined region without external referrals 
was investigated retrospectively by screening the medical records of patients diagnosed 
with CLL 1991-2010 within the Stockholm region. In total, 1479 patients were diagnosed 
with CLL within the time period. The medical files from 1301 (88%) patients were 
available for review and identified 92 patients as fludarabine (or cladribine (n=6)) 
refractory with 22% classified as DR, 40% as BFR and 38% as non-BFR/DR. Median age 
was 69 years and 67% had Rai-stage III/IV with median 3 prior therapies. The number of 
previous treatment lines was fewer in BFR and non-BFR/DR patients than in DR being 2, 2 
and 4 respectively. ORR was 20%, significantly lower in BFR (8%) and DR (20%) than in 
non-BFR/DR (31%). Median time to treatment failure (TTF) was 6 months, significantly 
longer in non-BFR/DR (9.2 months) than in BFR/DR (5.3/4.4 months) and significantly 
longer in antibody-treated patients (9.1 months) compared to other regimens (5.2 months). 
Early-death occurred in 5% and ≥ grade III infections in 20%. Median OS was 18 months, 
29 in BFR vs 13 in DR (p =0.054). Male sex was the only prognostic factor on OS. 
Patients with DR or BFR CLL are groups where new anti-CLL agents are often 
evaluated in non-randomized phase II trials and conditioned approval of new drugs are 
currently often based on data obtained in such trials. Patients selected for clinical trials are 
rarely representative of the general disease population. Thus there is a need for data from 
“real-world” clinical care to compare and complement data obtained from pivotal trials. 
The Stockholm area with its Regional Cancer Registry provides an opportunity to obtain 
comprehensive data on patients treated in a well-defined geographical region without 
external referrals, thereby minimizing selection bias. The results of this study provide data 
which could be instrumental in judging the safety/efficacy of new agents before subsequent 
phase III randomized trials are completed. An example was provided by the comparison to 
the results from the pivotal trial of ofatumumab [206] with a subgroup in our study matched 
those included in the trial. This comparison showed that corresponding patients in this 
study had a lower response rate (10-15%) to salvage therapy compared to those in the 
pivotal trial (47-58%). However, TTF and OS were comparable and the incidence of early 
deaths and major infections similarly low. The comparison showed that even though the 
trial [206] had relatively broad inclusion criteria, still 25% of the BFR/DR patients would not 
have been includable highlighting that trial patients were not truly representative of patients 
in routine clinical care. Compared to a previous study operating in a different healthcare 
environment (MD Anderson Cancer Center (MDACC)) [186] the patients in that study were 
10 years younger and had received more prior lines of therapy. However neither the ORR 
nor TTF was very different. Both studies show a shorter OS for DR patients compared to 
BFR patients confirming the great need for new treatment options in this patient group. Our 
study was also able to point out that BFR patients have a particularly low response rate as 
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well. However, there were some striking differences between the two studies. The risks of 
early death as well as the incidence of major infections were lower in our study (3-5% and 
16-20% vs. 10-16% and 45-60%) and the OS was longer (DR 13 vs. 8 months, BFR 29 vs. 
14 months). The reasons may be multifactorial but might reflect a more ill and heavily 
pretreated group of patients in the MDACC study [186]. 
An interesting finding was the differences in outcome following patients treated with 
antibodies, where the MDACC study reports poor effects (no responders and short OS) 
whereas in our study the corresponding group appeared to perform better in most outcome 
analyses. A further evaluation of the effectiveness of antibody treatment in our region was 
made in Paper II. Another striking finding was that male sex was the only baseline 
prognostic factor that reached statistical significance. This finding remains unexplained but 
might have been influenced by the fact that there were twice as many male than female 
subjects in the analysis. The lower statistical power in this study may have contributed to 
the inability to confirm findings from previous regression analyses [186] but does probably 
not explain all the differences. Limitations of our study are its retrospective nature and the 
relatively long time period during which regimens used might have changed. The same 
problems were evident in the MDACC study. However, no differences in survival were 
found in patients treated in the first decade compared to subsequent years in any of the 
studies which is in contrast to the improved OS measured from initial diagnosis [81] and 
further underlines the great need of new treatment options for patients with fludarabine 
refractory CLL. 
In conclusion, our results on “real-world” consecutive patients may facilitate 
interpretation of non-randomized trials on novel drugs in advanced-stage CLL. 
6.2 Paper II 
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients 
with relapsed/refractory chronic lymphocytic leukemia (CLL) – a single region 
experience on consecutive patients 
Eketorp Sylvan et al. Annals of Hematology, 93(10):1725-1733, 2014 
The safety/efficacy of alemtuzumab, when used in routine health care at experienced 
medical centers in a well-defined region (Stockholm), was evaluated in patients with 
relapsed/refractory CLL. Records from patients diagnosed year 1991-2010 were 
retrospectively screened and files from patients treated with alemtuzumab were analyzed in 
detail. The ability to review the majority of records is a key strength of our study as 
selection bias is minimal.  
In total, records from 1301 patients identified 56 includable patients. The median age 
was 69 years, 84% had advanced Rai stage, and at least 23% had bulky lymphadenopathy. 
The median number of prior lines of therapy was 3. Most patients (86%) had received 
treatments with purine analogues with 73% and 13% being in the Refractory and Purine 
analogue relapsed groups respectively. The median cumulative dose of alemtuzumab was 
930 mg, higher for responders (1063 mg) compared to non-responders (643 mg). As 
expected, a higher dose was associated with higher response rate. The ORR was 41%, 
including 7% CR/nPR (nodular partial remission), and the median duration of therapy was 
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12 weeks. The response rate was significantly associated with subgroup being 32.5% in the 
Refractory, 50% in the Purine analogue relapsed and 87.5% in the Relapsed subgroup. 
There was also a trend towards a survival effect by group. When new drugs are evaluated 
in clinical trials and published, results from patients are often pooled as one combined 
relapsed/refractory (R/R) cohort. However, the results in our study indicate that separate 
analyses of relapsed and refractory patients are recommended. In line with previous data 
[194], a better performance status was predictive of response. The median TTF was  
7.8 months. Major infections (≥ grade III) occurred in 36% of the patients. Opportunistic 
infections affected 21%, CMV reactivation being the most common and with a frequency 
in line with previous reports [194, 339]. Median OS was 22.5 months. Responders had a longer 
survival than non-responders, although the difference when using the Landmark method 
[337] was not significant, confirming that survival in relation to response must be analyzed 
with caution. Predictive factors for longer survival were better performance status and 
fewer prior treatment lines. We also observed a trend towards better survival for patients 
without bulky lymphadenopathy. In previous reports, the outcome with alemtuzumab 
treatment appeared poorer in routine clinical care [198, 339] than in clinical trials [172, 194]. 
However, despite aggravating baseline characteristics, the ORR in our study was at least as 
good as in previous reports [172, 174, 194, 198, 339] and survival was comparably long. A possible 
explanation might be the higher cumulative dose/longer duration of therapy observed in our 
study. A higher dose being significantly associated with response rate supports this 
hypothesis. Patients with advanced CLL in our region are usually treated by physicians 
with a great interest in CLL and we have a long-lasting experience in the use alemtuzumab, 
starting already in the early 1990s. Other data have shown better outcome for patients 
treated by physicians specialized in CLL [340]. Possibly by optimal identification of patients 
and management of predictable toxicities, such physicians may be able to avoid early 
discontinuation. The limitations of our study include the relatively small number of 
patients, a great number of unknown cytogenetics and the relatively long observation 
period (1991–2010) during which regimens used prior to alemtuzumab have changed. Due 
to the retrospective nature of the study, it was difficult to grade adverse events with 
certainty and not all records were found. However those not found were predominantly 
from outside the hospitals where alemtuzumab is not used. 
In conclusion, our results suggest that optimal patient management and patient 
identification may result in avoidance of early discontinuation of planned therapy and 
possibly better treatment outcomes. 
6.3 Paper III 
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic 
leukaemia: maintaining immune functions during therapy-induced immunosuppression 
Eketorp Sylvan et al. British Journal of Haematology, 159:599-613, 2012 
The safety and efficacy of lenalidomide in combination with alemtuzumab was explored in 
a phase 1 study and the capacity of low-dose lenalidomide in maintaining immune 
functions in advanced-stage CLL patients prior and during alemtuzumab was evaluated. 
Twelve consecutive patients with refractory CLL were enrolled and treated with 
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lenalidomide alone the first cycle and lenalidomide/alemtuzumab in combination cycle 2-4. 
Most patients were elderly, had advanced-phase, unmutated CLL, large lymph nodes and 
poor-prognosis cytogenetics. Due to early progressions on a starting dose of 2.5 mg 
lenalidomide, 6 patients started on 5 mg/d after protocol amendment. Half of the patients 
completed planned lenalidomide and 75% completed planned alemtuzumab treatment. 
Reasons for early withdrawal included progressive disease and neutropenia. 
The combination showed an acceptable safety profile as well as clinical activity with 
an ORR of 42%, all PR. Responding patients received a median lenalidomide-dose of 495 
mg (range 42–625) and non-responders 162 mg (range 50-532). Altogether these results 
suggest that a relatively high lenalidomide starting dose is required to avoid early 
progression, as previously reported [309]. Median PFS was 5 months, exceeding 12 months 
in 3 patients. TFR occurred in 4 patients, who were all responders, supporting that TFR 
may precede clinical responses [308, 309, 319]. There was no evidence of TLS. The most 
common grade III-IV adverse-events were neutropenia, which was also a dose-limiting 
toxicity, and thrombocytopenia (75% each). The maximum tolerated dose of lenalidomide 
in this combination was 10 mg/d, but most side effects occurred early on low-dose 
lenalidomide alone. 
Immune stimulation was already apparent after 4 weeks on low dose lenalidomide, 
indicated by a significant increase in the proportion of activated (HLA-DR+) CD4 and CD8 
T cells. A sustained activation was revealed by HLA-DR co-expression on both T cell 
subsets at the end of treatment. 
T cells showed a significantly increased proportion of CD28-expression and T cell 
proliferation (PPD/PHA stimulation) showed a non-significant increasing trend at week 4. 
We observed a gradual decrease in the proportion of Tregs not only during week 1–4 but 
also over the course of the combined treatment. The magnitude of change at week 4 
correlated with cumulative dose of lenalidomide. A numerical, but not significant, increase 
in absolute numbers of CD4 and CD8 T-cells and NK-cells was observed at week 4 and at 
the end of treatment the CD4 counts appeared higher than after alemtuzumab alone [194, 203]. 
However, no relationship between T-cell activation and clinical response was observed but 
the number of patients was too small to draw a conclusion. 
In contrast to others [301, 302, 309], we found neither any upregulation of CD80/86/40 or 
Fas-L nor increased immunoglobulin levels but a trend in the opposite direction for 
immunoglobulins. Possible explanations for discrepancies might be different doses of 
lenalidomide as well as length of therapy and also because patients in our study were 
heavily pretreated with advanced disease and therefore immunocompromised. 
In conclusion, our results provide the basis for an extended phase 2 trial on this 
combination of drugs as well as further studies on lenalidomide as an immune-enhancing 
agent. 
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6.4 Paper IV 
Sensitivity of chronic lymphocytic leukemia (CLL) cells to small targeted therapeutic 
molecules: an in vitro comparative study 
Eketorp Sylvan et al. Manuscript 
For drugs in early clinical testing it is of interest to analyze their in vitro killing capacity in 
head-to-head comparative experiments. We provide such a manufacturer independent, 
academic comparison on sensitivity of CLL cells to a panel of emerging small targeted 
therapeutic molecules using high-throughput screening based on an automated fluorescence 
digital scanning system. The in vitro anti-tumor effects of 31 emerging small therapeutic 
molecules were investigated on fresh CLL cells, thereby minimizing possible artifacts, 
from 42 consecutive patients with indolent (n=22) or progressive (n=20) CLL. Most 
progressive patients were relapsed and half of them were also fludarabine refractory. 
Culturing in a unique medium, OmniSanguine, prevents early apoptosis of CLL cells thus 
allowing long enough culturing (72 hrs.) to evaluate the full effects of the investigated 
drugs, including those with a less pronounced cytotoxicity. The pattern of effectiveness for 
drugs at 24 and 48 hours remained similar at 72 hours and the comparison with RPMI 
medium showed a significantly better survival of CLL cells in OmniSanguine altogether 
supporting the preserved viability of the CLL cells in this medium. 
The sensitivity to each drug showed considerable inter-patient variability. Highest 
mean direct killing was observed with one survivin inhibitor (YM-155), 2 BCL-2 inhibitors 
(ABT-199, ABT 737) and one selective CDK inhibitor (dinaciclib) showing a mean KE% 
of 67, 70, 70 and 67, respectively. These 4 molecules were effective also on samples from 
clinically more advanced patients. Regarding BCL-2 inhibitors and dinaciclib, our results 
are in line with previous studies [61, 285] which indicated high anti-tumor activity despite poor 
clinical prognostic markers. A pairwise comparison of drugs with similar molecular targets 
showed strong correlation but interestingly, the survivin inhibitor YM-155, showed no 
clear-cut correlation with any of the other drugs. YM-155 has also the most equal 
effectiveness in progressive and indolent patients, in heavily pretreated and untreated, as 
well as in fludarabine-resistant and -sensitive patient samples. Little is known about YM-
155 but it has been shown to overcome microenvironment mediated cell protection 
independently of prognostic markers [341]. Our results suggest that clinical trials may be 
warranted on this compound. Clinically promising drugs such as ibrutinib and idelalisib 
had a KE% of less than 12. This finding is in line with previous observations [243, 262] where 
induction of apoptosis with these drugs was modest. Their major clinical effect may not be 
due to direct cytotoxicity but, at least partly, by modulating the interaction between CLL 
cells and the microenvironment. 
Control experiments using cytostatic agents confirmed previous findings with a high 
killing capacity for daunorubicin [336]. An unexpectedly low KE% of bendamustine led to 
supplementary analysis with a stepwise drug titration up to 200 times higher concentration. 
However, when recalculating the previously described values into KE%, the effect in our 
system was comparable. In contrast to other drugs tested, the sensitiveness to 
corticosteroids did not appear to be dose-dependent which is somehow contradictious to 
clinical results with high dose steroids [182]. The KE of small molecules was, in contrast to 
most cytostatics, similarly high in refractory and untreated patients and for the four most 
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effective small molecules it was significantly higher on cells with TP53 disruptions, a 
finding that needs to be confirmed in an extended analysis.  
To evaluate KE in different compartments, the sensitivity of bone marrow was 
compared to cells from the blood. Since stromal cells were not separated from CLL cells in 
the bone marrow the microenvironment was, at least partly, preserved. Sensitivity in bone 
marrow showed a high correlation to that in blood and the drugs with the highest KE 
showed no difference between compartments. 
In conclusion, even though direct killing may not be the only therapeutic effector 
function in vivo, our results may help to identify potent drugs with multi-compartment 
activity of particular interest for further clinical development. 
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7 FUTURE PERSPECTIVES 
Extensive basic research has unraveled multiple factors underlying CLL. This has created 
prerequisites for development of drugs targeting key pathways, such as the BCR and 
antiapoptotic pathways, or redirecting the immune system towards the malignant cells. The 
evolution of increased therapeutic options in combination with the heterogenetic clinical 
course demands routine health care data for comparison with phase II study results. Patients 
in clinical trials are rarely representative of those in routine health care which is supported 
by our comparison in Paper I. The choice of treatment in routine health care is indeed 
driven by effectiveness but also convenience and cost. The choice of comparative treatment 
in trial may be affected by company interests, thus not necessarily and fully reflecting the 
treatments that are often used in clinical practice. Comprehensive, “real-world” data might 
help to interpret the cost-effectiveness of new drugs and our studies in Paper I and II add to 
the understanding of advanced CLL. An extended study investigating all patients in 
Sweden diagnosed with CLL 2007-2014 is ongoing. This study will evaluate treatments 
first-line as well as in the relapsed situation and additionally analyze whether type of health 
care unit and adherence to national guidelines influence patient outcome. 
The watch and wait strategy might be challenged by new therapies. In patients who 
harbor ever-so-tiny TP53 defective subclones at diagnosis early intervention with 
chemotherapy might select resistant clones. These patients shall when treatment is 
imminent, achieve therapies effectively targeting the unfavorable subclones. Early-
intervention trials need to be carefully assessed as the standard endpoint PFS may not be 
fully relevant in this setting. Our published (Paper I and II) and future planned studies may 
help to interpret such data. However, the situation may be different with new drugs. On one 
hand, an early intervention with new agents might be able to prevent disease onset or 
development thereby possibly avoiding the progressive accumulation of dismal genetic 
alterations during disease progression. On the other, early treatment may increase the risk 
of inducing resistance mechanisms, such as shown with kinase inhibitors. The low CR rate 
with BCR pathway inhibitors and the constant decline in PFS and OS curves suggest that 
very long-term remissions are unlikely with single agent therapy. Even though ABT-199 
might be effective on small subclones harboring TP53 lesions [61] and resistance to ibrutinib 
may be overcome by other BCR inhibitors such as CC292 [259], SYK- or PI3Kδ inhibitors 
[255] resistance might occur if single agent therapy is used. Carefully designed studies of 
combinations of drugs with different mechanisms of action are needed to circumvent the 
issues related to clonal diversity and to achieve long lasting remissions or perhaps even 
cure. 
“Sequential triple T“ (tailored, targeted, total eradication of MRD) is a recently 
suggested strategy of combining therapies [342]. Briefly it consists of three steps; debulking, 
induction and maintenance. Debulking is indicated when high lymphocyte counts  
(> 30,000/µL) or bulky lymphadenopathy is present. It is thought to be a short therapy  
(1-2 months) with mainly chemotherapy. However, chemotherapy might select aggressive 
subclones and the effect would probably be limited in patients with TP53 disruptions. 
Drugs targeting the BCR signaling might be a better option for these patients and the 
favorable toxicity profile of these drugs makes combinations, which reduce peripheral 
lymphocyte counts, interesting to investigate. Induction, part two in “sequential triple T“, 
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may consist of a combination of antibodies and a kinase- or a BCL-2-inhibitor. This phase 
is supposed to last as long as the remission continues to improve (4-6 months) and MRD 
assessment is performed 3 months after CR. Ibrutinib combined with rituximab was 
effective and tolerable but without impressive CR rates. However the effectiveness of 
single agent rituximab in CLL is limited. Combining ibrutinib with a more potent, 
compartment-selective monoclonal antibody might render better responses, even with 
MRD negativity. A phase I/II study investigating ibrutinib in combination with 
alemtuzumab is planned by our group. The effectiveness of alemtuzumab in clearing the 
blood and bone marrow in combination with the effect of ibrutinib on lymph nodes has the 
potential of longer and deeper responses. The CD20 antibody obinutuzumab might be an 
alternative considering the achieved MRD negativity [161]. Combinations with BTK or PI3K 
inhibitors and other small molecules appear attractive for further investigation as well. Our 
study in Paper IV provides some suggestions for such combinations (dinaciclib, ABT-199, 
or YM-155). In vitro the combination of ABT-199 and ibrutinib showed synergistic 
apoptosis in B cells, but no effect on normal T cells [343]. However, our study (Paper IV) is 
unable to completely evaluate the impact of the microenvironment. Therefore we plan an 
extended study, where lymph node specimens will be incubated with and without stromal 
cells, for evaluation of small molecules CLL killing capacity. The third part (Triple T) is 
maintenance with the aim to maintain a very good remission. Immunotherapy might be an 
attractive option in this part as tumor burden is supposed to be low. Lenalidomide is 
immunstimulating even in low doses, as shown in Paper III. A large randomized placebo-
controlled study is investigating it as maintenance but preliminary data are not yet available 
(NCT 00774345). Lenalidomide might also be effective as a vaccination adjuvant and we 
have an ongoing trial in previously untreated patients with slowly progressive CLL but 
without treatment indication, who receive lenalidomide in a dose-escalation schedule 
together with autologous tumor-loaded DCs. Early data showed an acceptable tolerability 
for low-dose lenalidomide as immune adjuvance and induced specific immune responses 
[344]. A combination with an anti-PD-1 antibody or ibrutinib might enhance the 
immunostimulatory effect. Which drug, or combination, to use for maintenance is not 
stated but single agents with favorable toxicity profiles, such as lenalidomide, antibodies or 
kinase inhibitors appears reasonable. However, long-term use of kinase inhibitors might 
possibly favor resistance mechanisms. Targeted therapy against ROR-1, an antigen 
selectively expressed on B-cell CLL but not on normal B cells and other major adult tissues 
might be a future treatment option using either monoclonal antibodies [75] or a kinase 
inhibitor [345]. Also CAR-T cells against ROR-1 have been developed and preclinical data 
appears promising [346]. Monitoring of the maintenance is performed by MRD assessment 
and treatment would probably last for 1-2 years even though the duration remains to be 
clarified. 
In summary, the future CLL-therapy algorithms will offer an increased number of 
possibilities and result in decreased morbidity and mortality. Even though cure still seems 
to be far ahead, an emerging transition of CLL from a disease with an often fatal outcome, 
to a truly chronic disease is in sight of the horizon. However, this demands further and 
intensified translational research in order to reach effective personalized cancer medicine.  
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